Protocol IRC00 5  Page 1 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 
Protocol Number: IRC -005 
 
A Randomized Double -Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer 
versus Low -Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A  
 
 
 
Sponsored by:  
[CONTACT_916] (OCRPRO)  
Division of Clinical Research (DCR)  
National Institute of Allergy and Infectious Diseases (NIAID)  
[ADDRESS_323310]  
Bethesda, MD [ZIP_CODE]  
 
 
 
 
Conducted by: 
[CONTACT_141571] (NIRC)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IND #: [ZIP_CODE] 
Version: 3.0 
Date: June 15, 2017 
  
Protocol IRC00 5  Page 2 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 
Table of Contents  
1 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  .........................  13 
1.1 Influenza  ................................ ................................ ................................ ................................ ... 13 
1.2 Passive Immunotherapy in Influenza  ................................ ................................ .....................  13 
1.2.1  Summary of Previous Pre -Clinical Studies  ................................ ................................ .. 13 
1.2.2  Summary of Previous Clinical Studies  ................................ ................................ .......... 14 
1.3 Study Rationale  ................................ ................................ ................................ ........................  18 
1.3.1  Discussion of Design and Controls  ................................ ................................ ................  18 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ......... 20 
2.1 Primary Objective  ................................ ................................ ................................ ....................  20 
2.2 Secondary Objectives  ................................ ................................ ................................ ...............  20 
3 INVESTIGATIONAL PLAN  ................................ ................................ ..............................  21 
3.1 General  ................................ ................................ ................................ ................................ ...... 21 
3.2 Definitions  ................................ ................................ ................................ ................................ . 21 
3.3 Overview  of Study Design  ................................ ................................ ................................ ....... 21 
4 STUDY POPULATION  ................................ ................................ ................................ ....... 22 
4.1 Inclusion Criteria for Enrollment (Screening)  ................................ ................................ ...... [ADDRESS_323311] asma Preparation ................................ ................................ ................................ ....... 26 
5.9 Study Plasma Administration  ................................ ................................ ................................ . 26 
5.10  Plasma Accountability  ................................ ................................ ................................ .............  27 
5.11 Concomitant Medications ................................ ................................ ................................ ........  27 
5.12  Prohibited Medications ................................ ................................ ................................ ............  28 
5.13  Treatment Compliance  ................................ ................................ ................................ ............  28 
6 STUDY PROCEDURES  ................................ ................................ ................................ ...... 28 
6.1 Schedule of Evaluations  ................................ ................................ ................................ ...........  28 
Protocol IRC00 5  Page 3 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
6.2 Location and Personnel for Study Procedures  ................................ ................................ ...... 30 
6.3 Detailed Description of Assessments  ................................ ................................ ......................  30 
6.3.1  Study Day 1 to 0: Screening  ................................ ................................ .........................  30 
6.3.2  Determination of Eligibility  ................................ ................................ ...........................  32 
6.3.3  Study Day 0: Baseline Evaluation and Randomization  ................................ ............... 32 
6.3.4 Study Plasma Administration  ................................ ................................ ........................  33 
6.3.5  Study Day 1 ................................ ................................ ................................ ......................  34 
6.3.6  Study Day 2 ................................ ................................ ................................ ......................  34 
6.3.7  Study Day 3................................ ................................ ................................ ......................  35 
6.3.8  Study Day 7 (±1)  ................................ ................................ ................................ .............. 36 
6.3.9  Study Day 14 (±2)  ................................ ................................ ................................ ............ 37 
6.3.10 Study Day 28 (Day 28 -32) ................................ ................................ ...............................  38 
6.4 Special Pregnancy Follow -up Visit  ................................ ................................ .........................  38 
7 MEASURES OF EFFICACY, SAFETY, AND PHARMACOKINETICS  .....................  38 
7.1 Pharmacokinetic Measures  ................................ ................................ ................................ ..... 38 
7.2 Influenza A Diagnostics - Viral Shedding  ................................ ................................ ..............  38 
7.3 Efficacy Measures  ................................ ................................ ................................ ....................  38 
7.3.1  Ordinal Scale  ................................ ................................ ................................ ...................  38 
7.3.2  NEW Score  ................................ ................................ ................................ ......................  39 
7.3.3  PEW Score ................................ ................................ ................................ .......................  40 
7.3.4  SOFA Score  ................................ ................................ ................................ .....................  40 
7.3.5  PELOD Score  ................................ ................................ ................................ ..................  42 
7.3.6  ARDS ................................ ................................ ................................ ...............................  44 
7.3.7  Measures of clinical support  ................................ ................................ ..........................  44 
7.3.8  Efficacy Measures Not Used  ................................ ................................ ..........................  44 
7.4 Safety Evaluations  ................................ ................................ ................................ ....................  45 
7.4.1  Laboratory Evaluations  ................................ ................................ ................................ . 45 
7.5 Research Tests  ................................ ................................ ................................ ..........................  45 
8 RISKS/BENEFITS  ................................ ................................ ................................ ................  45 
8.1 Potential Risks  ................................ ................................ ................................ ..........................  45 
8.1.1  Risk of Plasma Transfusions  ................................ ................................ ..........................  45 
8.1.2  Risk of Phlebotomy  ................................ ................................ ................................ ......... 48 
8.1.3  Risk of Oropharyngeal Swab  ................................ ................................ .........................  48 
8.2 Potential Benefits  ................................ ................................ ................................ .....................  48 
8.2.1  Benefits of Treatment  ................................ ................................ ................................ ..... 48 
8.2.2  Benefits of Diagnosis  ................................ ................................ ................................ ....... 48 
8.2.3  Alternatives ................................ ................................ ................................ ......................  48 
9 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS AND DATA  ...... 48 
9.1 Intended Use of the Samples/Specimens/Data  ................................ ................................ ....... 48 
9.2 Storage of Samples/Specimens/Data  ................................ ................................ .......................  48 
Protocol IRC00 5  Page 4 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
9.3 Storage of Genetic Sample  ................................ ................................ ................................ ...... 48 
9.4 Tracking Samples/Specimens/Data  ................................ ................................ ........................  49 
9.5 Use of Samples/Specimens/Data at the Completion of the Protocol  ................................ .... 49 
9.6 Reporting Loss or Destruction of Samples/Specimens/Data  ................................ ................  49 
10 ASSESSMENT OF SAFETY  ................................ ................................ ...............................  49 
10.1  Definitions  ................................ ................................ ................................ ................................ . 49 
10.2  Documen ting, Recording, and Reporting Adverse Events  ................................ ...................  50 
10.2.1  Assessment of Adverse Event  ................................ ................................ .........................  51 
10.2.2  Severity ................................ ................................ ................................ ............................  51 
10.2.3  Causality  ................................ ................................ ................................ ..........................  52 
10.3  Investigator Reporting Responsibilities to the Sponsor  ................................ .......................  52 
10.3.1  Adverse Events  ................................ ................................ ................................ ................  52 
10.3.2  Serious Adverse Events  ................................ ................................ ................................ .. 53 
10.3.3  Unanticip ated Problems  ................................ ................................ ................................ . 53 
10.4  Safety Reporting for Off Study Subjects  ................................ ................................ ...............  53 
10.5  Investigator Reporting Responsibilities to the IRB  ................................ ..............................  53 
10.6  Sponsor’s Reporting Responsibilities  ................................ ................................ .....................  53 
10.7  Safety Oversight  ................................ ................................ ................................ .......................  54 
10.7.1  Protocol Team Monitoring Plan  ................................ ................................ ....................  54 
10.7.2  Sponsor Medical Monitor ................................ ................................ ...............................  54 
10.8  Data and Safety Monitoring Plan  ................................ ................................ ...........................  54 
10.9  Pausing Rules  ................................ ................................ ................................ ...........................  55 
11 STUDY M ONITORING  ................................ ................................ ................................ ...... 55 
12 STATISTICAL CONSIDERATIONS  ................................ ................................ ................  55 
12.1  General Considerations  ................................ ................................ ................................ ...........  55 
12.2  Sample Size and Power Considerations  ................................ ................................ .................  56 
12.3  Statistical Analysis  ................................ ................................ ................................ ...................  57 
12.4  Endpoints  ................................ ................................ ................................ ................................ .. 58 
12.4.1  Primary Endpoint  ................................ ................................ ................................ ........... 58 
12.4.2  Secondary Endpoints  ................................ ................................ ................................ ...... 58 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................ .........................  58 
13.1  IRB/IEC Approval  ................................ ................................ ................................ ...................  58 
13.2  Compliance with Good Clinical Practices (GCP)  ................................ ................................ . [ADDRESS_323312] Selection  ................................ ................................ ..............  59 
13.4.1  Inclusion of Children  ................................ ................................ ................................ ...... 59 
13.4.2  Inclusion of Pregnant Women  ................................ ................................ .......................  59 
13.4.3  Inclusion of Subjects Unable to Provide Informed Consent  ................................ ....... 59 
13.4.4  Justification of Exclusions  ................................ ................................ ..............................  59 
13.5  Anonymity and Confidentiality  ................................ ................................ ..............................  60 
Protocol IRC00 5  Page 5 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323313] Retention ................................ ................................ ................................ ...........  60 
15 REFERENCES  ................................ ................................ ................................ ......................  62 
16 APPENDIX A  ................................ ................................ ................................ ........................  64 
 
  
Protocol IRC00 5  Page 6 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323314] of Figures  
 
Figure 1: a) Therapeutic Efficacy of F(ab)[ADDRESS_323315] H5N1; b)  Efficacy of Passive 
Immunoprophylaxis Against H5N1  ................................ ................................ .........................  13 
Figure 2: a) Proportion of participants with normalized respi[INVESTIGATOR_265841], by 
[CONTACT_29673] (ITT population); b) Proportion of participants with normalized 
respi[INVESTIGATOR_265841], by [CONTACT_29673] (modified ITT population - 
excluding participants with normalized respi[INVESTIGATOR_265842])  ..............................  15 
Figure 3: a) Proportion of p articipants without ARDS present over time, by [CONTACT_29673] 
(ITT population restricted to subjects with ARDS at baseline); b) Proportion of 
participants with 20% improvement in score, by [CONTACT_29673] (ITT population) 
– Adults ................................ ................................ ................................ ................................ ...... 15 
Figure 4: Influenza H1N1, H3N1 and B HAI titer over time, by [CONTACT_82153]  .........................  [ADDRESS_323316] of Tables  
 
Table 1: Summary of hospi[INVESTIGATOR_307]/ICU stays and supplemental oxygen/mechanical ventilation during 
study follow -up, by [CONTACT_29673]  ................................ ................................ ............. 16 
Table 2: Disposition following last hospi[INVESTIGATOR_2345], by [CONTACT_29673] (ITT population)  18 
Table 3: Proposed primary endpoint (clinical status measured on a 6 -point ordinal scale) applied to 
IRC002 data (post -hoc analysis)  ................................ ................................ ..............................  18 
Table 4: B/Mass H3N2 HAI titer over time, by [CONTACT_82153] (as -treated population) among 
those with Influenza Type B  ................................ ................................ ................................ ..... 20 
Table 5: Schedule of Evaluations  ................................ ................................ ................................ ............. 29 
Table 6: NEW Score  ................................ ................................ ................................ ................................ . 39 
Table 7: P EW Score  ................................ ................................ ................................ ................................ .. 40 
Table 8: Use of SpO 2/FiO2 in SOFA Score  ................................ ................................ ..............................  41 
Table 9: PELOD Scoring System  ................................ ................................ ................................ ............ 43 
Table 10: Berlin Criteria for ARDS  ................................ ................................ ................................ ........ 44 
Table 11:  SAEs seen in IRC002  ................................ ................................ ................................ .............. 47 
Table 12: Anticipated Distribution of Subjects in the Ordinal Scale  ................................ ...................  56 
 
  
Protocol IRC00 5  Page 7 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323317] OF ABBREVIATIONS  
AE Adverse Event/Adverse Experience  
ALT Alanine Aminotransferase  
Anti-HBc Hepatitis B Core Antibodies  
APACHE  Acute Physiology And Chronic Health Evaluation (Score) 
ARDS Acute Respi[INVESTIGATOR_265843] [ADDRESS_323318]  
ISBT International Society of Blood Transfusion  
IVIG Intravenous Immune Globulin  
IWRS Interactive Web Response System  
MAP Mean Arterial Pressure  
MOP Manual of Operations  
NAT Nucleic Acid Testing  
NA Neuraminidase  
NEWS (NEW score)  National Early Warning Score  
NIAID National Institute of Allergy And Infectious Diseases 
NIRC NIAID Influenza Research Collaboration  
OCRPRO  Office of Clinical Research Policy And Regulatory Operations  
Protocol IRC00 5  Page 8 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
OP Oropharyngeal  
OTC Over the Counter  
PCR Polymerase Chain Reaction  
PELOD Pediatric Logistic Organ Dysfunction  
PEWS (PEW score)  Pediatric Early Warning Score  
PK Pharmacokinetic  
SAE Serious Adverse Event  
SERF Safety Expedited Report Form  
SOFA Sequential Organ Failure Assessment  
SSS Social & Scientific Systems, Inc.  
TACO Transfusion -Associated Circulatory Overload  
TRALI Transfusion -Related Acute Lung Injury  
UP Unanticipated Problem  
UPnonAE  Unanticipated Problem that is not an Adverse Event  
  
Protocol IRC00 5  Page 9 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
PROTOCOL SUMMARY  
Full Title:  A Randomized Double -Blind, Phase 3 Study Comparing the Efficacy and Safety 
of High-Titer versus Low -Titer Anti -Influenza Immune Plasma for the Treatment 
of Severe Influenza A  
 
Short Title:  IRC-005 
 
Clinical Phase:  3 
 
IND Sponsor:  OCRPRO, NIAID  
 
Conducted by:  [CONTACT_141571] (NIRC)  
 
Sample Size:  150  
Accrual Ceiling:  Up to 300 subjects will be screened to randomize 150 subjects  
 
Study Population:  Subjects aged two weeks or older , including children and pregnant women, 
hospi[INVESTIGATOR_265844]  A infection 
 
Study Duration:  November 2015 – November 2018  
 
Study Design:  This randomized, double-blinded, multicenter Phase 3 trial will assess the 
efficacy and safety of anti -influenza immune plasma (also referred as “anti -
influenza plasma ”) as an addition to standard of care antivirals in subjects 
hospi[INVESTIGATOR_265844] A infection (as defined in the inclusion 
criteria). Up to 40 sites in the [LOCATION_002] will participate in this protocol. 
Adults and children may participate. There is no exclusion for pregnancy.  
 
 A total of 150 eligible subjects will be randomized in a 2:1 ratio to receive either 
high-titer anti-influenza plasma or control (low -titer) plasma . All subjects will 
receive standard care antivirals.  Randomization will be stratified by:  
 Severity: in the intensive care unit (ICU), non -ICU hospi[INVESTIGATOR_265845], or non -ICU hospi[INVESTIGATOR_265846] .  
 Age category (child/adult)  
  
Subjects will be assessed on Day 0 ( baseline) and on Days 1, 2, 3, 7, 14, and 28. 
For participants who are not hospit alized on Days 2, 14, and 28, contact [CONTACT_265909].  
All subjects will undergo a series of efficacy, safety, and hemagglutination 
inhibition (HAI) assessments during the study. Blood samples will be col lected 
on Day 0, 1, 3, and 7 . Oropharyngeal ( OP) swabs for influenza PCR will be 
obtained on Days 0 and 3.  
Study Agent : All plasma is from male donors to minimize the risk of transfusion -related acute  
lung injury  (TRALI). The high-titer arm will receive human plasma with 
influenza A/H1N1 and A/H3N2 HAI titers of at least 1:80. The sponsor will try 
to supply units with as high a HAI as possible. The antigens for the HAI will be 
Protocol IRC00 5  Page 10 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
for contemporary strains defined as strains contained within that year’s seasonal 
trivalent influenza vaccine.  
  
The control (low-titer) arm will receive human plasma with influenza A/H1N1 
and A/H3N2 HAI titers of 1:10 or less .  
 
Primary Objective:  Evaluate the efficacy of treatment with high -titer versus low -titer anti-influenza 
immune plasma  as an addition to standard care in subjects hospi[INVESTIGATOR_265847] A  by [CONTACT_265910] 7 . 
 
Primary Endpoint:  Subject clinical status at Day 7 (6-point ordinal scale): 
1. Death 
2. In ICU 
3. Non-ICU hospi[INVESTIGATOR_059], requiring supplemental oxygen  
4. Non-ICU hospi[INVESTIGATOR_059], not requiring supplemental oxygen  
5. Not hospi[INVESTIGATOR_057], but unable to resume normal activities  
6. Not hospi[INVESTIGATOR_265848]:  1. Evaluate the efficacy and safety of treatment with high -titer versus low -titer 
anti-influenza immune plasma  plus standard care , using the following 
parameters:  
 Subject clinical status (6 -point ordinal scale)  at Days 1, 2, 3, 14 , and 28  
 Duration of initial hospi[INVESTIGATOR_059]  
 28-day mortality  
 In-hospi[INVESTIGATOR_265849]  
 Composite of mortality and hospi[INVESTIGATOR_265850] 7, 14 , and 28  
 Change from baseline to Day 3 and Day 7 in National Early Warning 
(NEW)/ Pediatric Early Warning (PEW) score  
 Duration of supplemental oxygen use among those requiring oxygen at 
randomization  
 Incidence of new oxygen use during the study  
 Duration of ICU stay among those requiring ICU admission at 
randomizati on 
 Incidence of new ICU admission during the study  
 Duration of mechanical ventilation use among those requiring mechanical 
ventilation at randomization  
 Incidence of new mechanical ventilation use during the study  
 Duration and severity of acute respi[INVESTIGATOR_1505] ( ARDS) 
among those meeting the definition of ARDS at randomization  
 Incidence and severity of new ARDS during the study  
 Duration of  extra corporeal membrane oxygenation  (ECMO) use among 
those requiring ECMO at randomization  
 Incidence of new ECMO use during the study  
 Change from baseline to Day 3 and Day 7 in sequential organ failure 
assessment (SOFA ) score for age ≥ 18 years, and pediatric logistic organ 
dysfunction (PELOD ) score for age < 18 years  
 Disposition (home, rehabilitation, chro nic nursing facility, initial 
hospi[INVESTIGATOR_265851] 28 days, died in hospi[INVESTIGATOR_307]) following the initial 
hospi[INVESTIGATOR_265852]00 5  Page 11 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 Percent of  subjects with influenza virus detectable  in OP sample at Day 3 
 
 2. Compare the plasma and control groups for HAI titer s at Days 1, 3 , and 7. 
 
3. Evaluate the safety of high titer anti-influenza plasma as compared to low titer 
plasma as assessed by:  
 Cumulative incidence of grade 3 and grade 4 adverse events (AEs)  
 Cumulative incidence of serious adverse events  (SAEs) 
 
 
 
  
Protocol IRC00 5  Page 12 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323319] care antivirals for the 
treatment of severe influenza A . Hospi[INVESTIGATOR_265853] A will be eligible for study 
participation. Up to 40 sites in the [LOCATION_002] will participate in this protocol.  Adults and children may 
participate. There is no exclusion for pregnancy.  
A total of 150 eligible subjects will be randomized in a 2:1 ratio to receive either high-titer anti-influenza 
plasma or control (low -titer) plasma . All plasma is from male donors t o minimize the risk of TRALI .  
Subjects will be assessed on Study Day 0 ( baseline) and on Study Days 1, 2, 3, 7, 14, and 28. For 
participants who are not hospi[INVESTIGATOR_265854] 2, 14, and 28, contact [CONTACT_265911].  Study visits on Days 1, 3, [ADDRESS_323320] occur in person. All subjects will undergo a series of efficacy , safety, and HAI assessments during 
the study. Blood samples will be collected on Day 0, 1 , 3, and 7. OP swabs for influenza PCR will be 
obtained on Days 0 and 3.  
P r o t o c o l  I R C 0 0 5  P a g e  1 3  o f  6 4   
I N D  1 4 2 2 9  C O N F I D E N T I A L  1 5 J U N 2 0 1 7 ;  V e r s i o n  3 . 0  
 
1 B A CKG RO U N D  I N FO RM A T IO N  A N D  S C I E N T I F I C  R A T IO N A L E  
1 . 1  I n f l u e n z a  
D e s p i t e  a n t i v i r a l s  a n d  v a c c i n e s ,  i n f l u e n z a  i s  r e s p o n s i b l e  f o r  2 2 6 , 0 0 0  e x c e s s  h o s p i t a l i z a t i o n s  a n d  3 0 , 0 0 0  - 
5 0 , 0 0 0  d e a t h s  e a c h  y e a r  i n  t h e  U n i t e d  S t a t e s  a l o n e . [1] T h e  n um b e r  o f  d e a t h s  i s  e s t im a t e d  t o  b e  o v e r  
5 0 0 , 0 0 0  w o r l d w i d e .  C i r c u l a t i n g  H 1 N 1  a n d  H 3 N 2  i s o l a t e s  a r e  h i g h l y  r e s i s t a n t  t o  am a n t a d i n e  a n d  
r im a n t a d i n e ,  a n d  c o n s e q u e n t l y ,  t h e s e  d r u g s  a r e  n o t  t h e r a p e u t i c .  C u r r e n t l y ,  t h e  c i r c u l a t i n g  s t r a i n s  a r e  
s u s c e p t i b l e  t o  o s e l t am i v i r  a n d  z a n am i v i r .  P r e v i o u s  c i r c u l a t i n g  s e a s o n a l  H 1 N 1  i n f l u e n z a  v i r u s e s  h a v e  
h i g h -l e v e l  r e s i s t a n c e  t o  o s e l t am i v i r .  A d d i t i o n a l l y ,  r e s i s t a n c e  t o  o s e l t am i v i r  o c c u r r i n g  o n  t h e r a p y  h a s  b e e n  
d e s c r i b e d  i n  s e a s o n a l  a n d  a v i a n  i n f l u e n z a .  [2] D u e  t o  t h e  m o r b i d i t y  a n d  m o r t a l i t y  o c c u r r i n g  d e s p i t e  
t r e a tm e n t  w i t h  c u r r e n t  a n t i v i r a l s  a s  w e l l  a s  t h e  l im i t e d  t h e r a p e u t i c  o p t i o n s  f o r  i n f l u e n z a ,  a d d i t i o n a l  
t h e r a p e u t i c s  f o r  i n f l u e n z a  a r e  w a r r a n t e d .  O n e  p o t e n t i a l  t h e r a p e u t i c  t h a t  i s  f a i r l y  r a p i d l y  a v a i l a b l e  i s  t h e  u s e  
o f  h i g h -t i t e r  a n t i -i n f l u e n z a  imm u n e  p l a sm a .  
1 . 2  P a s s i v e  Imm u n o t h e r a p y  i n  I n f l u e n z a  
1 . 2 . 1  S umm a r y  o f  P r e v i o u s  P r e -C l i n i c a l  S t u d i e s   
O n e  sm a l l  s t u d y  i n  a  B A L B / c  m o u s e  m o d e l  d em o n s t r a t e d  t h e  t h e r a p e u t i c  e f f i c a c y  o f  F ( a b ) 2  f r a gm e n t s  
a g a i n s t  a  l e t h a l  d o s e  o f  H 5 N 1  v i r u s .  [3] I n  t h i s  m o d e l ,  t h e  m i c e  r e c e i v e d  a n  i n t r a p e r i t o n e a l  i n j e c t i o n  o f  5 0 ,  
1 0 0 ,  o r  2 0 0  µ g  F ( a b ) 2 f r a gm e n t s /m o u s e  w i t h  n o rm a l  h o r s e  a n t i b o d y  a s  a  c o n t r o l ,  2 4  h o u r s  a f t e r  i n f e c t i o n .  
F i f t y  m i c r o g r am s  o f  a n t i -H 5 N 1  F ( a b ) 2 g a v e  7 0%  p r o t e c t i o n ,  a n d  1 0 0  a n d  2 0 0  µ g  o f  a n t i -H 5 N 1  F ( a b )2 
g a v e  1 0 0%  p r o t e c t i o n .  I n  c o n t r a s t ,  t h e  a n t i b o d y -n e g a t i v e  c o n t r o l  ( 2 0 0  µ g  o f  n o n imm u n e  e q u i n e  a n t i b o d y )  
d i d  n o t  p r o v i d e  p r o t e c t i o n ,  a n d  a l l  t h e  m i c e  i n  t h i s  g r o u p  d i e d  ( 
F i g u r e  1a) .  
 
 
      
 
 
 
 
 
 
F i g u r e  1:  a )  T h e r a p e u t i c  E f f i c a c y  o f  F ( a b ) 2  F r a gm e n t s  A g a i n s t  H 5 N 1 ;  b )  E f f i c a c y  o f  P a s s i v e  
Imm u n o p r o p h y l a x i s  A g a i n s t  H 5 N 1   
 
R e s e a r c h e r s  a t  S t .  J u d e  C h i l d r e n ’ s  R e s e a r c h  H o s p i t a l  t e s t e d  t h e  p r o p h y l a c t i c  e f f i c a c y  o f  c o n v a l e s c e n t  
p l a sm a .  E l e v e n -w e e k -o l d  m i c e  w e r e  i n t r a p e r i t o n e a l l y  i n j e c t e d  w i t h  3 5 0  µ L  o f  s e r um  c o l l e c t e d  f r om  m i c e  
t h a t  s u r v i v e d  c h a l l e n g e  w i t h  A / V i e t n am / 1 2 0 3 / 0 4  ( H 5 N 1 )  v i r u s  a f t e r  2  d o s e s  o f  a n  i n f l u e n z a  
n e u r am i n i d a s e  ( N A )  e n c o d i n g  D N A  v a c c i n e .  A  n e g a t i v e  c o n t r o l  s e r um  w a s  p o o l e d  f r om  s a l i n e -i n j e c t e d  
m i c e  (F i g u r e  1b ) . R e c i p i e n t  m i c e  w e r e  c h a l l e n g e d  w i t h  1 0  M L D 5 0  o f  A / V i e t n am / 1 2 0 3 / 0 4  1 8  h o u r s  a f t e r  
p a s s i v e  imm u n i z a t i o n .  [4] T h e  m i c e  t h a t  r e c e i v e d  t h e  imm u n e  p l a sm a  w e r e  1 0 0%  p r o t e c t e d .  
Protocol IRC00 5  Page 14 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
1.2.2 Summary of Previous Clinical Studies  
[IP_ADDRESS] [ADDRESS_323321] been beneficial in the treatment of 
influenza pneumonia and ARDS.  [5]  
[IP_ADDRESS] Hong Kong H1N1 2009 Plasma C ohort Study 
A cohort study was conducted in Hong Kong by [CONTACT_30224] 93 patients aged > 18 years with severe H1N1 
2009 infection requiring intensive care. [6] All subjects were offered treatment with 500 mL of 
convalescent plasma with a neutralizing H1N1 2009 antibody titer of > 1:160, collected from patients 
recovering from H1N1 2009 infection. Twenty subjects (21.5%) agreed to receive the plasma treatment, 
and [ADDRESS_323322] antiviral treatment and other supportive medical 
care. Clinical outcome was compared in the subjects treated with plasma with those who declined plasma 
treatment as the “untreated” controls. Mortality in the treatment group was significantly lower than in the 
control group (20.0% vs. 54.8%; P = .01). The acute physiology and chronic health evaluation 
(APACHE ) score in the control arm was 13. For similar severity of illness as measured by [CONTACT_265912], mortality from H1N1 in other series is reported a s 20-25%. [7-10] There were no adverse events 
(AEs) attributed to the convalescent plasma.  
[IP_ADDRESS] Hong Kong H1N1 2009 IVIG Randomized Controlled Trial 
A multi-center, prospective, double -blind, randomized controlled trial of a hyperimmune intravenous 
immunoglobulin was also conducted in Hong Kong. [11] Convalescent plasma from patients who 
recovered from the 2009 pandemic influenza infection was made into an immunoglobulin (H -IVIG). 
Patients with severe A/H1N1  infection on standard antiviral treatment requiring inte nsive care and 
ventilatory support were randomized to receive H -IVIG or normal IVIG. Thirty -five patients were 
randomized to receive H -IVIG (17 patients) or IVIG (18 patients). H -IVIG treatment was associated with 
significantly lower day [ADDRESS_323323] -treatment viral load when compared to the control (p=0.04 and 
p=0.02 respectively). Subgroup multivariate analysis of the 22 patients who received treatment within 5 
days of symptom onset demonstrated that H -IVIG treatment was the only factor that independently  
reduced mortality [OR: 0.14, 95% CI, 0.02 -0.92; p=0.04].  
[IP_ADDRESS] IRC002 – Severe Seasonal Influenza Plasma Randomized Trial  
The NIAID Influenza Research Collaboration (NIRC)  conducted a randomized study using high -titer anti-
influenza plasma . Subjects of any age  were eligible if they had confirmed influenza A or B and had 
evidence of severe influenza defined as oxygen s aturation of < 93% on room air or tachypnea (respi[INVESTIGATOR_862] > 20 for adults, with higher rates defined for children) . Ninety-eight subjects were  enrolled between 
January [ADDRESS_323324] care (including antivirals) or standard care plus 2 units of high -titer anti-influenza 
plasma defined as influenza A/H1N1 and A /H3N2, or influenza B HAI titer of at least 1:40. The primary 
endpoint was proportion of participants with normalized respi[INVESTIGATOR_265841] . The final study 
analysis is noted below . 
At baseline (Day 0) , 82% required oxygen, 4 3% were on mec hanical ventilation, 58% were in the ICU, 
and 38% met criteria for a cute respi[INVESTIGATOR_1505]  (ARDS). Five subjects in the standard care 
arm and one subject in the plasma treatmen t arm died (ITT, logrank p=0.093 ). Fifty-three percent  of 
subjects in the standard care arm and 6 7% of subjects in the plasma treatment arm normalized re spi[INVESTIGATOR_265855] 28 (ITT  logrank p=0.069 ; Figure 2a). More subjects in the plasma treatment arm 
normalized respi[INVESTIGATOR_265856] [ADDRESS_323325] ill a trend towards effic acy in the plasma treatment 
Protocol IRC00 5  Page 15 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
arm (ITT logrank p=0. 26; Figure 2b). The treatment effect was primar ily seen in subjects randomized 
within 4 days  of symptoms.  
 
Figure 2: a) Proportion of participants with normalized respi[INVESTIGATOR_265841], by [CONTACT_265913] (ITT population); b) Proportion of participants with normalized respi[INVESTIGATOR_265857], by [CONTACT_29673] (modified ITT population - excluding participants with 
normalized respi[INVESTIGATOR_265842])  
 
Similar trends of efficacy were seen in proportion of subjects with out ARDS (Figure 3a) and 
improvement of SOFA score ( Figure 3b). 
  
Figure 3: a) Proportion of participants without ARDS present over time, by [CONTACT_29673] (ITT 
population  restricted to subjects with ARDS at baseline ); b) Proportion of participants with 
20% improvement in score, by [CONTACT_29673] (ITT population) – Adults 
 
Similar trends in efficacy were seen i n days of hospi[INVESTIGATOR_059], days in the ICU, and days on mechanical 
ventilation ( Table 1). No benefit was seen in days on oxygen ( Table 1), resolution of symptoms , fever, or 
viral shedding (data not shown).  

Protocol IRC00 5  Page 16 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Table 1: Summary of hospi[INVESTIGATOR_307]/ICU stays and supplemental oxygen/mechanical ventilation during study 
follow-up, by [CONTACT_265914]002 protocol required units to have an HAI of ≥ 1:40, the plasma units used for influenza A 
generally had an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80, and for influenza B the HAI 
titer was closer to 1:40. The HAI titers o ver time are the equivalent of pharmacokinetics  (PK) for this 
intervention. The subjects ’ serum was tested to contemporary strains (i.e. , not all subjects were tested to 
all strains). In the plasma arm, this intervention raised the HAI for influenza A/H1N1 from 1:29 to 1:63 at 
Day 2 and 1:81 at Day 4 (standard care: 1:32 on Day 0, 1:40 on Day 2, 1:41 on Day 4). A similar increase 
was seen i n A/H3N2. However, in influenza B , the HAI in the active and standard care arms were similar 
and did not increase significantly by [CONTACT_2006] 2 . 
                         
Table	 2:	 Disposition	 and	 other	 secondary	 endpoints	 by	 [CONTACT_265915]	 (PEP)
TotalAnti-influenza Plasma + 
Standard CareStandard Care Alone
(N=87) (N=42) (N=45)
Median (Q1, Q3) 9 (4, 21) 6 (4, 16) 11 (5, 25) 0.13
1 78 (90%) 40 (95%) 38 (84%) 0.096
2 7 (8%) 2 (5%) 5 (11%)
4 2 (2%) 0 (0%) 2 (4%)
No 32 (37%) 18 (43%) 14 (31%) 0.097
Yes - 1 or more epi[INVESTIGATOR_1841] 50 (57%) 24 (57%) 31 (69%)
Median (Q1, Q3) 3 (0, 12) 2.5 (0.0, 9.0) 3 (0, 13) 0.37
No 12 (14%) 8 (19%) 4 (9%) 0.61
Yes - 1 or more epi[INVESTIGATOR_1841] 75 (86%) 34 (81%) 41 (91%)
Median (Q1, Q3) 8 (2, 28) 7 (1, 28) 8 (3, 28) 0.52
No 43 (49%) 24 (57%) 19 (42%) 0.12
Yes - 1 or more epi[INVESTIGATOR_1841] 44 (51%) 18 (43%) 26 (58%)
Median (Q1, Q3) 1 (0, 11) 0 (0, 6) 3 (0, 14) 0.14
*Wilcoxon rank sum 
P-Value*Randomized treatment
Mechanical ventilation
Days on mechanical ventilationDays on supplemental oxygenSupplemental oxygenDays in hospi[INVESTIGATOR_265858]00 5  Page 17 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 
                       
 
 
 
Figure 4: Influenza H1N1, H3N1 and B HAI titer over time, by [CONTACT_265916], there was a trend in higher level of disposition after hospi[INVESTIGATOR_2345], with more subjects in the 
plasma treatment arm returning home, and more subjects in the control arm b eing hospi[INVESTIGATOR_53481] 28  
(Table 2).  

Protocol IRC00 5  Page 18 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Table 2: Disposition following last hospi[INVESTIGATOR_2345], by [CONTACT_29673] (ITT population)  
 
Another way to analyze treatment efficacy is to compare the clinical status of patients in the plasma and 
standard care groups at 7 days using an ordinal scale of 6 clinical states.  This analysis is used in the 
INSIGHT anti -influenza IVIG study, and is pro posed as the primary endpoint for the current study. When 
this ordinal scale is applied to the IRC002 data, there is good evidence of efficacy  (Table 3).  
 
Table 3: Proposed primary endpoint (clinical status measured on a 6 -point ordinal scale) applied to 
IRC002 data (post -hoc analysis)    
              
 
1.3 Study Rational e 
Of subjects hospi[INVESTIGATOR_265844] (combining both IRC002 tr eatment groups together ), 29% 
remained in the ICU and 60% had died or remained in the hospi[INVESTIGATOR_52965] 7  (Table 3). There is need for 
better treatments in this population. The data from IRC002 strongly suggests that the addition of high -titer 
immune plasma to standard care can improve outcomes in this po pulation. This present study aims to 
confirm these results in a continued search for better treatments  for severe influenza .  
1.3.1 Discussion of Design and Controls  
IRC002 was randomized, but not blinded and with no control intervention. While the primary endpoint 
chosen was objective (normalization of oxygenation and respi[INVESTIGATOR_697] ) and should not be influenced by 
[CONTACT_265917], there remains the potential f or bias influencing the study results. For example, the 
follow-up rate in IRC002 was less for those subjects randomized to receive standard care. Thus, assuring 
a completely blinded study was seen as critical for this study.  
Table	 2:	 Disposition	 and	 other	 secondary	 endpoints	 by	 [CONTACT_265915]	 (PEP)
TotalAnti-influenza Plasma + 
Standard CareStandard Care Alone
(N=87) (N=42) (N=45)
Released home - home health care not required 35 (41%) 21 (50%) 14 (33%) 0.029
Released home with home health care 13 (15%) 7 (17%) 6 (14%)
Transferred to long term care facility 12 (14%) 6 (14%) 6 (14%)
Hospi[INVESTIGATOR_265859] 28 18 (21%) 7 (17%) 11 (26%)
Discharged to hospi[INVESTIGATOR_3677] - home or inpatient 1 (1%) 0 (0%) 1 (2%)
Deceased 6 (7%) 1 (2%) 5 (12%)Disposition after last hospi[INVESTIGATOR_2345] 
P-Value*Randomized treatment
  Randomized 
treatment  
 Total 
(N=87) P+S 
(N=42) S 
(N=45) P-Value* 
Category at Day 7 N 87 42 45 0.020 
  Not hospi[INVESTIGATOR_265860] 25 (29%) 17 (40%) 8 (18%)  
 Not hospi[INVESTIGATOR_057], but unable to resume normal activities 6 (7%) 5 (12%) 1 (2%)  
 Non-ICU hospi[INVESTIGATOR_059], not requiring supplemental oxygen 5 (6%) 0 (0%) 5 (11%)  
 Non-ICU hospi[INVESTIGATOR_059], requiring supplemental oxygen 19 (22%) 7 (17%) 12 (27%)  
 In the intensive care unit (ICU) 27 (31%) 13 (31%) 14 (31%)  
 Death 5 (6%) 0 (0%) 5 (11%)  
 *Wilcoxon Test 
 
Protocol IRC00 5  Page 19 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Several control arm interventio ns were considered for this study:  
 Double Blind , with low-titer control plasma. This intervention would be easiest to blind. 
Additionally, it explicitly tests the hypothesis that the anti -influenza antibodies (as detected by 
[CONTACT_35363]) are the component of plasm a responsible for any treatment effect seen.  
 Double Blind , with 5% albumin . The control would consist of adding 5% albumin to saline and 
putting it in a plasma bag with a standard ISBT label. It was thought that this may look like 
plasma from a distance, b ut by [CONTACT_265918]. Blood Establishment 
personnel would be effectively unblinded. Due to the appearance, all units would have to be 
placed in an opaque bag, but hospi[INVESTIGATOR_265861] p er 
standard blood transfusion policies. Additionally, it was considered that the hospi[INVESTIGATOR_265862] “normal” plasma. This would likely unblind the 
nurse administering the plasma. So additional staff would hav e to be used. However, even with 
these additional steps, it was considered unlikely that the blind could be maintained.  
 Single Blind , with 5% albumin. This would blind subjects, but not blind the study team. This was 
considered more feasible due to some of  the considerations above. However, single blind was not 
likely to add much scientific rigor above an unblinded study.  
 No Blind, no control - similar to IRC002. The increased lost to follow -up rate in the control arm 
was attributed in part due to subjects not seeing value in participating in a study for which they 
were not “chosen” to receive the proposed treatment. Additionally, there is the concern that while 
the endpoints are objective the biases of investigators can never be completely excluded .  
 
After careful considerations of all options, the use of low -titer plasma was seen as the best control, and 
would allow a fully blinded study to be performed.  
Under IND [ZIP_CODE], the international study INSIGHT 006 (FLU -IVIG) is a multicenter, double -blind, 
randomized, placebo -controlled clinical trial comparing treatment with hyperimmune intravenous 
immunoglobulin (IVIG) versus saline placebo in hospi[INVESTIGATOR_265863] A 
or B who have a NEW score ≥ 2. By [CONTACT_265919], prima ry endpoint , and some secondary 
endpoint data between this plasma study and the FLU -IVIG study, additional study analysis can compare 
high-titer plasma vs . IVIG and high -titer plasma vs . saline to determine if treatment effect (if confirmed) 
is due to IgG or other components in human plasma. Therefore, this study was designed to have similar 
assessments, days of assessments, etc., to the INSIGHT 006 study.  
A NEW score (or PEW score) of 3 is used in this IRC005 study. The use of this score along with the 
requirement for hospi[INVESTIGATOR_265864] a population that is hospi[INVESTIGATOR_265865]. The IRC002 study required only hypoxia 
or tachypnea to be enrolled. By [CONTACT_265920], either of these criteria would be a score of 2. Eight 
percent of the IRC002 adult population with influenza A would be excluded by [CONTACT_2329] a cut off of NEW 
score ≥ 3, but the NEW score also  allows enrollment of population with severe influenza that did not 
quite meet the IRC002 population so is unlikely to decrease enrollment .  
Subjects with i nfluenza B only are excluded from the IRC005 study. In IRC002, influenza B made up 
only 7% (7 subjec ts) of the study population. In general, it is hard to find units with high HAI titers to 
influenza B, so the cutoff of units used in the IRC002 study was 1:40. Analyzing the HAI titers for the 7 
subjects with influenza B, it is not clear (though the numbe rs are very small) that the plasma -treated arm 
had higher HAI titers ( Table 4). So for reasons of both low incidence and low HAI titers, this study wil l 
not enroll subjects with influenza B.  
 
Protocol IRC00 5  Page 20 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Table 4: B/Mass H3N2 HAI titer over time, by [CONTACT_82153] (as -treated population) among those 
with Influenza Type B  
 
[ADDRESS_323326]’s  clinical status at Day 7 on a 6-point ordinal s cale: 
1. Death 
2. In the ICU  
3. Non-ICU hospi[INVESTIGATOR_059], requiring supplemental oxygen  
4. Non-ICU hospi[INVESTIGATOR_059], not requiring supplemental oxygen  
5. Not hospi[INVESTIGATOR_057], but unable to resume normal activities  
6. Not hospi[INVESTIGATOR_52091]  
2.[ADDRESS_323327] care , using the following parameters : 
 The ordinal primary outcome assessed at Days 1, 2, 3, 14 , and 28  
 Duration of initial hospi[INVESTIGATOR_059]  
 28-day mortality  
 In-hospi[INVESTIGATOR_265849]  
 Composite of mortality and hospi[INVESTIGATOR_265850] 7, 14 , and 28  
 Change from baseline to Day 3 and Day 7 in NEW /PEW score  
 Duration of sup plemental oxygen use among those requiring oxygen at randomization  
 Incidence of new oxygen use during the study  
 Duration of ICU stay among those requiring ICU admission at randomization  
 Incidence of new ICU admission during the study  
 Duration of mechanical  ventilation use among those requiring mechanical ventilation at 
randomization  
 Incidence of new mechanical ventilation use during the study  
 Duration and severity of ARDS among those meeting the definition of ARDS at 
randomization  
 Incidence and severity of new ARDS during the study  
 Duration of ECMO use among those requiring ECMO at randomization  
 Incidence of new ECMO use during the study  
 Change from baseline to Day 3 and Day 7 SOFA score for age ≥ 18 years, and PELOD score 
for age < 18 years 
 Disposition (hom e, rehabilitation, chronic nursing facility, initial hospi[INVESTIGATOR_265851] 
28 days, died in hospi[INVESTIGATOR_307]) following the initial hospi[INVESTIGATOR_265866]00 5  Page 21 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 Percent of subjects with influenza virus detectable in OP sample at Day 3  
 
2. Compare the plasma and control groups for HAI t iters at Days 1, 3 , and 7. 
3. Evaluate the safety of high titer anti-influenza plasma as compared to low titer plasma  as assessed by:  
 Cumulative incidence of grade 3 and grade 4 adverse events (AEs)  
 Cumulative incidence of serious adverse events (SAEs) 
 
[ADDRESS_323328] of males and females hospi[INVESTIGATOR_265844] A. 
3.2 Definitions  
Definitions for the purpose of this study:  
 Enrolled:  For the purpose of collecting data and sample s, and reporting AEs, a subject will be 
considered enrolled beginning from when the informed consent form is signed until the subject is 
considered “screen failure”, “discontinued”, or “completed”.  
 
 Randomized:  For the purpose of study reporting and data analysis, subjects are considered 
randomized  when a randomization number is assigned.  
 
 Screen Failures:  Subjects are considered screen failures  when they meet one of the following 
criteria after signing consent:  
◦ Screening tests reveal that the subject is  ineligible.  
◦ Subject withdraws consent before being randomized.  
 
 Discontinued:  Subjects are considered discontinued  when they meet one or both of the following 
criteria: 
◦ Subject withdraws consent after being randomized (refer to Section 4.4). 
◦ Subject is withdrawn by [CONTACT_265921] (refer to Section 4.5). 
 
 Completed:  Subjects are considered completed  when they are followed through Study Day 28 or 
followed through to death at or prior to 28 days.  
3.3 Overview of Study Design  
This randomized, double-blinded, multicenter Phase 3 trial will assess the efficacy and safety of high-titer 
versus low-titer anti-influenza immune plasma for the treatment of severe influenza A . Hospi[INVESTIGATOR_265867] A (as defined in the inclusion  criteria) will be eligible for study 
participation. Up to 40 sites in the [LOCATION_002] will participate in this protocol. Adults and children may 
participate. There is no exclusion for pregnancy.  
A total of 150 eligible subjects will be randomized in a 2:1 ratio to receive either high-titer or low titer 
(control) anti-influenza plasma on Study Day 0  (refer to Section 5.7– Plasma Dose ). All subjects will 
receive standard care antivirals (generally this would be oseltamivir).  
Protocol IRC00 5  Page 22 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Subjects will be assessed on Study Day 0 ( baseline) and on Study Days 1, 2, 3, 7, 14, and 28. For 
participants who are not hospi[INVESTIGATOR_265854] 2, 14, and 28, contact [CONTACT_265922] . 
All subjects will undergo a series of efficacy , safety, and PK (HAI) assessments during the study. Blood 
samples will be col lected on Day 0, 1, 3, and 7 . OP swabs for influenza PCR will be obtained on Day 0 
and 3.  
4 STUDY POPULATION  
4.1 Inclusion Criteria for Enrollment (Screening)  
1. Subjects must be aged 2 weeks or older.  
2. Hospi[INVESTIGATOR_265868]: The decision for hospi[INVESTIGATOR_265869] . To be considered eligible, t he 
hospi[INVESTIGATOR_265870], or a  prolongation of a hospi[INVESTIGATOR_80334] a 
respi[INVESTIGATOR_265871]. Influenza could be a component of a larger 
respi[INVESTIGATOR_7686] (i.e. COPD exacerbation th ought to be triggered by [CONTACT_14302]) . However, respi[INVESTIGATOR_265872] (i.e. a subject that had mild influenza 
then developed pulmonary embolism  and respi[INVESTIGATOR_265873] ). 
3. Study plasma available  on-site or available within [ADDRESS_323329] for influenza A (by [CONTACT_954], other nucleic acid testing, or by [CONTACT_265923]) from a specimen obtained ≤ 48 hours prior to randomization . 
2. Onset of illness ≤ [ADDRESS_323330] one respi[INVESTIGATOR_265874] . 
Note: For subjects with chronic respi[INVESTIGATOR_1856] (chronic cough, or COPD with baseline dyspnea), the 
onset of symptoms is defined as t he point when the symptoms changed during this illness).  
3. Hospi[INVESTIGATOR_265875], with anticipated hospi[INVESTIGATOR_88789] 24 hours  after 
randomization . Criteria for hospi[INVESTIGATOR_265876].  
4. NEW or PEW score ≥ 3 within 12 hours prior to randomization . 
5. ABO-compatible plasma available  on-site or available within 24 hours after randomization . 
 
4.3 Exclusion Criteria for Randomization  
Subjects who meet any of the following criteria will be excluded from study pa rticipation:  
1. Strong clinical evidence in the judgment of the site investigator  that the etiology of illness is 
primarily bacterial super-infection in origin. Co-infection would be allowed, as there may be 
benefit to resolving influenza illness faster. Supe r-infection, where influenza illness occurred and 
is resolving, and new bacterial illness causing deterioration should be excluded.  (e.g., if the 
subject’s respi[INVESTIGATOR_265877], this 
exclusion criteria would be met).  
2. Prior treatment with any anti-influenza investigational drug , anti-influenza investigational IVIG, 
or anti-influenza investigational plasma therapy within 30 days prior to screening . Other 
investigational drug therapi[INVESTIGATOR_014] (n on-influenza) and administration of plasma and/or IVIG for non -
influenza reasons are allowed .  
3. History of allergic reaction to blood or plasma products (as judged by [CONTACT_6962]) . 
Protocol IRC00 5  Page 23 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323331] the individual at a substantially increased risk of thrombosis (e.g., cryoglobulinemia, severe 
refractory hypertriglyceridemia, or clinically significa nt monoclonal gammopathy) . Prior IVIG 
use alone would not meet exclusion criteria, but the investigator should consider the potential for 
a hyper-coagulable state.  
5. Subjects who, in the judgment of the site investigator, will be unlikely to comply with the  
requirements of this protocol , including being uncontact[CONTACT_265924][INVESTIGATOR_307] . 
6. Medical conditions for which receipt of 450-700 mL (or pediatric equivalent) of intravenous fluid 
may be dangerous to the subject (e.g., decompensated congesti ve heart failure) . 
4.[ADDRESS_323332] Withdrawal  
Subjects (or their legal surrogates if subjects are or become unable to make informed decisions) can 
terminate study participation at any time without prejudice. Subjects who indicate interest in withdrawing 
from the s tudy should be asked  about possible limited further study data collection and/or  data usage,  
rather than full withdrawal. The most important data to obtain is safety data through Day 28  and primary 
endpoint data ( clinical status  at Day 7). This would require, at a minimum, a Day [ADDRESS_323333] 
for vital status (date of discharge, disposition, and any adverse events that occurred during the study)  and 
a review of the available subject information for clinical status at Day [ADDRESS_323334] by [CONTACT_265925]:  
 The subject is lost to follow-up. 
 The subject experiences an AE, including complications incurred during plasma infusion, and the 
investigator believes that continuation in the study would be detrimental to the subject.  In such 
cases, it is recommended that the subject remain in  the study with safety follow -up through Day 
28.  The option of continued participation with limited intervention or even just observational 
data collection should  be considered prior to investigator initiated discontinuation due to AE.  
Considerations for limited follow up are described in Section  4.4.  
 Non-compliance with s tudy procedures to the extent that it is potentially harmful to the subject or 
to the integrity of the study data.  
Lost to follow -up is defined as unsuccessful contact [CONTACT_265926].  
Any randomized subject withdrawn from th e study will not be replaced.  
4.6 Discontinuation of Study  
The Office of Clinical Research P olicy and Regulatory Operations ( OCRPRO ), as the study sponsor, and 
the Food and Drug Administration (FDA), have the right to terminate this study at one or all sites at any 
time. The reviewing IRB/IEC has the right to terminate the study at the sites it is responsible for at any 
time.  
Protocol IRC00 5  Page 24 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
5 TREATMENT  
Subjects will be randomized on Study Day 0 in a 2:[ADDRESS_323335] the following characteristics:  
 Negative Anti -HIV-1/2 
 Negative Anti-HTLV-I/II   
 Negative Anti -HCV 
 Negative HBsAg  
 Negative for anti -HBc 
 Negative serologic test for syphilis  
 Negative West Nile Virus (WNV) NAT  
 Negative HCV NAT  
 Negative HIV NAT  
 Negative for Zika NAT 
The blood establishments collecting the plasma follow a ll current FDA guidance .  
All plasma units used in this study  have anti-influenza antibodies to influenza A (A/H1N1 or A/H3N2)  as 
needed for this study . 
 Active arm will receive human plasma  (FFP or FP24 ) with both an influenza A /H1N1 and 
A/H3N2 HAI titer of at least 1:80. The sponsor will try to supply units with as high a HAI as 
possible. The antigens for the HAI will be for contemporary strains defined as strains contained 
within that year’s seasonal trivalent influenza vaccine .  
 Control arm will receive  human plasma  (FFP or FP24 ) with both an influenza A /H1N1 and 
A/H3N2 HAI titer of 1:10 or less .  
 Refer to Section 5.[ADDRESS_323336] the same label. Blood establishment personnel and study 
team will remain blinded  until after analysis . 
5.2 Randomization  
Subjects who meet all criteria for enrollment will be randomized using an interactive web response 
system (IWRS) to receive high-titer anti-influenza plasma or low-titer plasma  in a 2:1 ratio. A central 
randomization scheme has been prepared by [CONTACT_456]. Randomization is stratified by : 
 Severity: in the ICU, non -ICU hospi[INVESTIGATOR_265878], or non -ICU 
hospi[INVESTIGATOR_265879]   
 Age category (child/adult)  
Protocol IRC00 5  Page 25 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323337] udy 
Study plasma dosing is detailed in Section 5.7.  The total volume of plasma in adults can be estimated by 
[CONTACT_265927] 40 mL/kg. [12] For a 70-kg person, the plasma volume 
would be estimated to be 2800 mL (40 mL/kg x70 kg). For nonimmune subj ects assume this plasma 
volume has a HAI = 0.  
The volume of a unit of study plasma is approximately 250 mL (range 225 -350 mL). Therefore, the  adult 
study dose of 2 units of plasma would be equal to approximately 450-700 mL. A plasma volume of 500 
mL at a HAI titer of 1:160 would increase HAI in plasma to approximately 1:25. A plasma volume of 500 
mL at a HAI titer of 1:80 would increase HAI in plasma to approximately 1:13.  
In IRC002, in general , this model worked. Subjects receiving plasma had a geometric mean influenza 
A/H1N1 HAI titer of 1:2 6 on Day 0, 1:63 on Day 2, and 1:[ADDRESS_323338] care alone 
group had a HAI titer of 1: 30 on Day 0, 1:36 on Day 2, and 1:37  on Day 4. As expected , the titers on Day 
28 were essentially the same , (1:95 and 1:96 respectively) meaning any HAI incr ease from the plasma 
infusions is gone by [CONTACT_2006] 28 .  
For children and neonates, the  total volume of plasma  is estimated between 37.3  and 54.8 mL/kg. [13, 14] 
Using a mean of 45 mL/kg, a n anti-influenza plasma dose of 4 mL/kg would provide the same increase in 
HAI as would be expected in a [ADDRESS_323339] receiving 1 unit of plasma. The total dose of 2 units of 
plasma in adults is equiva lent to 8 mL/kg in children (either as one infusion or two infusions, as noted in 
Section 5.7). 
5.[ADDRESS_323340] be maintained  at -20°C or colder.  Any excursion warmer than -18°C should follow the 
site SOP re garding suitability for infusion . If the plasma is not useable  this should be documented , then a 
deviation should be filed and the spon sor should be notified .  
 
Any temperature excursion warmer than -20°C should be recorded and communicated  to the sponsor . 
While this plasma may be useable for infusion,  the temperature excursion may impact the plasma’s 
suitability for manufacturing (if units with high tit er antibody  are unused at the end of the season or at 
expi[INVESTIGATOR_1516] ). By [CONTACT_265928], the ultimate disposition of these 
units can be determined.  
 
Protocol IRC00 5  Page 26 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
5.7 Plasma Dose  
Specific study plasma unit(s), identified by [CONTACT_265929] (DIN), will be assigned to 
subjects in the IWRS.   
 Adult subjects will receive [ADDRESS_323341] is of very small weight and/or stature, and the  investigator thinks it is 
not safe to administer 2 units, then less than two full units can be administered and the 
reason for not administering the full two units should be described in the source 
documentation and  entered in  the eCRF. 
 Pediatric subjects ≥ 56 kg, will receive 8 mL/kg not to exceed 2 units of assigned study  plasma 
divided into 2 infusions (approximately 4 mL/kg of study plasma per infusion) (i.e. in larger 
children, this may be less than 8  mL/kg). Specify the total dose (volume) to be administered in 
the plasma order to ensure accurate dosing.  
 Pediatric subjects ≥ 28 kg but < 56 kg will receive 8 mL/kg of assigned study plasma divided into 
2 infusions (approximately 4 mL/kg of study plasma per infusion).  Specify the total dose 
(volume) to be administered in the plasma order to ensure accurate dosing.  
 Pediatric subjects < 28 kg will receive 8 mL/kg of assigned study plasma given in one infusion. 
The total dose of 8 mL/kg can be accomplished with one unit of plasma, thereby [CONTACT_265930]. Specify the total dose (volume) to be administered 
in the plasma order to ensure accurate dosing.  
 
Subject Type  Dosage Units of Plasma   
Adult  450 -700 mL 2 
Pediatric ≥ 56 kg 4 mL/kg + 4mL/kg= 8 mL/kg 
total (448-700 mL) 2 
Pediatric ≥ 28  kg but < 56 kg  4 mL/kg + 4mL/kg =8 mL/kg 
total ( < 448 mL)  2 
Pediatric < 28 kg  8 mL/kg (< 224 mL)  1 
 
5.8 Study Plasma Preparation  
After receipt of the IWRS randomization notification, t he appropriate s ite staff will order/ request the 
plasma by [CONTACT_265931] (s) included in  the randomization notification.  
Site blood bank/transfusion services should verify the plasma to be infused  and that the DIN (s) on the 
plasma unit(s) match the DINs specified in the plasma order , and should prepare the study plasma 
according to standard departmental procedures.  
The sponsor must be informed promptly of any study plasma units that are thawed but not administered to 
the assigned subject. If study plasma is thawed but not administered to the assigned subject , it must be 
destroyed in accordance with standard blood bank procedures.  When dosing pediatric subjects, any 
allocated unused  plasma must also be destroyed in accordance with s tandard blood bank procedures.  
5.[ADDRESS_323342] . The plasma infusion rate will be determined by [CONTACT_265932] .  
Protocol IRC00 5  Page 27 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Before administration of study plasma, the investigator (or designated study staff) must verify the plasma 
label(s) to confirm that the DIN (s) on the plasma unit(s) match the IWRS randomization notification 
email for the subject , as well as to confirm the appropriate  dose to be administered (refer to Section 5.7). 
Plasma DIN (s) and plasma product code (s) should be recorded in source documents at the time of 
infusion along with the volume administered . 
The calendar date and 24 -hour clock time for study plasma administration should be recorded for the start 
and end of each infusion. The intervals between units may occur per a site’s blood establishment SOPs 
and/or normal practice. Pretreatment to minimize  transfusion reactions  (e.g. acetaminophen, 
diphenhydramine , etc.) according to local institutional policies  are permitted in this study, but any such 
medications should be captured as concomitant medications.  
If an AE develops during infusion, the infusi on may be slowed temporarily or permanently discontinued, 
as deemed appropriate by [CONTACT_093]. As a guide, local side effects (e.g., infusion site burning) or 
non-allergic systemic effects (e.g., chills) can generally be alleviated by [CONTACT_265933] e of infusion, 
whereas allergic side effects (e.g., rash, wheezing, hypotension) should result in the cessation of study 
plasma infusion. All grade 3 or grade 4 AEs , and all SAEs occurring during study plasma administration 
should be captured as noted in S ection 10.2. Additionally, an y AEs resulting in plasma discontinuation 
(regardless of AE grade) shou ld be recorded.   
The investigator is ultimately responsible for  making the decision to slow or stop study plasma infusion. 
If the infusion is discontinued, the subject should be treated according to best available local practices and 
procedures, and the Medical Monitor should be notified.  Reason(s) for premature disco ntinuation of any 
plasma infusion must be documented in the medical record (source document) and on the eCRF. 
5.10 Plasma Accountability  
The investigator or his/her designee is required to maintain accurate study plasma accountability records. 
A binder containi ng instructions and the required accountability documentation will be provided to the 
investigator or his/her designee. When the study is completed, copi[INVESTIGATOR_265880]. Copi[INVESTIGATOR_265881]. All unused 
study plasma must be  returned to the repository or  disposed of upon authorization by [CONTACT_265934]. A ll records regarding the disposition of study plasma must be available for inspection by [CONTACT_265935].  
5.11 Concomitant Medications  
Subjects will be monitored throughout the study for use of concomitant medications. Any prescription 
medications including IVIG, blood products, over -the-counter (OTC) preparations, herbal remedies, 
and/or nutritional supplements taken during the study per iod must be recorded on the eCRF.  
All subjects with  confirmed  influenza infection will receive an anti -influenza antiviral (e.g., oseltamivir, 
zanamivir).  
It is also anticipated that subjects may be treated with antibacterial agents, either for concomita nt 
infection, or bacterial superinfection after influenza. The final decision for antibiotics (need, drug[s] , and 
dose) and other medications will be made by [CONTACT_1963] (except as noted below under  5.12 
Prohibited Medications).  
Protocol IRC00 5  Page 28 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323343] medical practice. This does not include licensed drugs available under a n emergency 
use authorizati on (EUA) or approved medications at unapproved doses . 
5.13 Treatment Compliance  
Deviation(s) from the prescribed dosage regimen should be recorded in the eCRF and the subject’s source 
document.  
[ADDRESS_323344] day after randomization  is Study Day 1, etc . If 
the plasma is not administered until the day after randomization, the day of randomization should still be 
noted to be Study Day 0 . 
In an attempt to standardize the data, the follow up study visits should preferably occur in the morning 
(i.e. prior to noon). However, any visit within the window (as defined on the schedule of ev aluations is 
acceptable).  
 
 
Protocol IRC00 5  Page 29 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Table 5: Schedule of Evaluations  
  Screen Base
line  Randomization  Study Plasma Administration  Follow-up 
Day +/- Window −1 to 0 0 0 0 1 2* 3 7 ± 1 14 ± 2* 28 + 
4* 
Time       Pre-
infusion 1st unit 
plasma 2nd unit 
plasma)5             
Evaluation/Procedure                          
ELIGIBILTY                          
Informed consent  X                       
Demographics & Medical History  X                       
Influenza A testing (PCR or rapid Ag)[ADDRESS_323345]     
 X                   
Plasma infusion          X X             
STUDY PROCEDURES     
                    
Vital signs including SpO2 X X  
X X X X X X X  X X  
Clinical Data3 X X  
      X X X X X X  
Concomitant medications    X  
X      X X X X X X 
Adverse events    X  
   X X  X X X X X X 
SAFETY LABORATORY     
                    
CBC, Chemistry Panel, and PT/INR4   X  
      X   X X     
Pregnancy test  (for females of childbearing potential)  X  
                    
RESEARCH  LABORATORY  PROCEDURES     
                    
Blood for Serum    X  
      X   X X     
Oropharyngeal Swab for virus isolation   X  
          X       
Notes: 
1. Influenza test  results from a specimen obtained ≤ 48 hours prior to randomization  may be used. 
2. Documented ABO typi[INVESTIGATOR_265882]; however, re -typi[INVESTIGATOR_265883].  
3. Refer to Section 6.3 of the protocol for details of clinical data to be collected . 
4. CBC includes white cell count with differential (including neutrophil,  and lymphocyte), hemoglobin, hematocrit, and platelets . Chemistry panel includes creatinine, glucose, total protein, total 
bilirubin, ALT/SGPT, AST/ SGOT). 
5. For Pediatrics < 28 kg, there is no second unit plasma infusion.  
* This visit may be conducted via telephone . If conducted via telephone, the assessments should be restricted to the ordinal scale, oxygen requirements, new medical condi tions, concomitant 
medication, and evaluation for AEs. 
Protocol IRC00 5  Page 30 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323346]:  
 IRB/IEC approval for home visits . 
 Written study -specific procedures including obtaining samples with the storage condition and 
timeframe of this protocol that are approved by [CONTACT_3476].  
 Documentation of institutional permission or policies permitting home visits including liability 
concerns. 
 Adequate staff and resources to perform home visits (e.g., portable pulse oximeter for SpO2 
measurements ).  
Data collected for clinical indications may be used (i.e. review of clinical chart) if obtained on the given 
day /within the specified window . Otherwise assessments need to be performed by [CONTACT_3476] . All 
study assessments should be performed by [CONTACT_265936] (according to site practices, local law , and as designated o n the 
appropriate study documents).  
6.3 Detailed Description of Assessments  
6.3.1 Study Day 1 to 0: Screening  
Subjects may be screened  in the emergency room  or hospi[INVESTIGATOR_307]. Screening evaluations must be completed 
before randomization.  
[IP_ADDRESS] Informed Consent  
One informed con sent form will be used for both screening and enrollment into this protocol . Informed 
consent must be obtained prior to performing any study related activities.  
The site investigator will review the informed consent document with the subject or legal repre sentative. 
Informed consent should be obtained from the subject, or if a subject is judged by [CONTACT_265937], consent should be obtained from his/her legally authorized 
representative. The use of a surrogate for c onsent may only be done if allowed by [CONTACT_265938] .  
As a guideline, children age 7 years or older should be presented the study assent (in addition to consent 
being obtained from his/her legally author ized representative). This age cutoff for assent may be adjusted 
for individual situations, and per institutional or site IRB policies/stipulations.  
Subjects who were previously unable to provide informed consent, but are able to do so on a given study 
day, should be re -consented for continued study participation.  If a subject becomes able to provide 
consent between visits, the subject should return to the center at the next study visit to provide consent 
unless institutional policies allow telephone conse nt. 
  
Protocol IRC00 5  Page 31 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
[IP_ADDRESS] Demographics  
After informed consent is obtained, t he following information should be recorded:  
 Age 
 Sex 
 Ethnicity  
 Race 
[IP_ADDRESS] Medical History  
The investigator (or designee) will take a medical history following  consent and conduct a complete 
physical examination. The following information should be recorded:  
 Day of onset of influenza symptoms  
 Influenza vaccin ation in the current season  
 History of chronic medical conditions  
 Any acute medical problems from the current hospi[INVESTIGATOR_059] (including laboratory abnormalities)  
 Current use of prescription and OTC medications  
 History of allergies  
 Additional history to be obtained from pregnant women includes last menstrual period, ultr asonic 
gestational age (if known), and complications during pregnancy.  
 For women who are not of childbearing potential, the reason for this (if known) should be 
documented.  
 
Medical conditions noted at the time of consent should be recorded in the eCRF. Any conditions that 
develop after consent should be recorded on the AE page of the eCRF. 
[IP_ADDRESS] Clinical Data at Screening  
 Vital signs, including SpO2. These values may be obtained from clinically collected information 
if they were obtained within 4 hours of the screening study assessment.  Vital signs should be 
collected in a complete set within 30 minutes of each other.  
 Early warning score  
 NEW score for age ≥ 18 years 
 PEW score for age < 18 years 
[IP_ADDRESS] Influenza Testing  
The subject should have a respi[INVESTIGATOR_92814] (n asal, throat, sputum, etc .) tested for influenza either by 
[CONTACT_265939], PCR, or DFA  that can detect influenza A. Test results from specimens  that were collected 
within [ADDRESS_323347] be repeated.  
[IP_ADDRESS] Laboratory Testing  
The following tests should be performed and/or prior results collected at screening:  
 Blood typi[INVESTIGATOR_007] (ABO).  
o Prior blood typi[INVESTIGATOR_265884] (as ABO 
typi[INVESTIGATOR_265885] a given individual) . Results from an active blood typi[INVESTIGATOR_007]  
(as per each institution’s policy ) must be available prior to release and administr ation of 
study plasma .  
Protocol IRC00 5  Page 32 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 Urine or serum pregnancy test  for females of childbearing potential . 
o Results from l aboratory tests obtained up to [ADDRESS_323348]’s assessment of risks/benefits, it should be done at the time of screening.    
o If a female subject is not of childbearing potential, the underlying cause (i.e. 
premenarche, post -menopause, hysterectomy, etc .) should be included in source 
documentation.  
6.3.[ADDRESS_323349] been completed (i.e., medical history, 
laboratory tests), the investigator  or designee  is to review the inclusion/exclusion criteria and determine 
the subject’s eligibility for study randomization .  
Baseline evaluations will not be completed for screen failures. Only t he following information will be 
collected on screen failures: demographics (age, screen number, sex, birth date, ethnicity, and race) and 
reason for ineligibility. Subjects who are found to be ineligible will be told the reason for ineligibility, and 
may not be re -screened for the study .  
Those subjects found eligible will have baseline data collected prior to randomization and plasma 
administration. Day [ADDRESS_323350] prior 
to randomization.  
6.3.3 Study Day 0: Baseline Evaluation  and Randomization  
[IP_ADDRESS] Baseline Clinical Data  
 Clinical data must be collected just prior to randomization (n o more than 4 hours between 
collection and randomization ). 
 Vital signs, including SpO2. These values may be obtained from clinically collected information  if 
they were obtained within 4 hours prior to randomization . Vital signs should be collected in a 
complete set within 30 minutes of each other . 
o This can be the same set of vital signs as used at screening as long  as they were obtained 
within 4 hours prior to randomization.  
 Clinical data: 
 Assessment of clinical status (6-point ordinal scale) 
 Glasgow coma scale  
 Early warning score  
 NEW score for age ≥ 18 years  
 PEW score for age < 18 years 
 Organ dysfunction score  
 SOFA score for age ≥ 18 years 
 PELOD score for age < 18 years 
 Measures of clinical support:  
 Hospi[INVESTIGATOR_059]  
 Oxygen requirement  
 Mechanical ventilator requirement  
 ICU requirement  
 ECMO requirement  
 Chest x-ray finding if performed for clinical indication  within 24 hours prior to 
randomization  
 Assessment of ARDS using PaO 2 (or SpO2), FiO 2, and recent chest x -ray data. 
Protocol IRC00 5  Page 33 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 Note: If the above-listed clinical data assessments were performed for screening and collected < 4 
hours prior to randomization, they do not need to be repeated for baseline assessment  unless the 
investigator believes there has been a likely change in the score based o n clinical assessment . 
  Review new medical conditions, co ncomitant  medication, and evaluate for AE s that have 
occurred after informed consent.  
[IP_ADDRESS] Baseline Clinical Safety Laboratory Tests  
Blood draws for t he following laboratory test s will be performed  prior to randomization and plasma 
administration . The results do not need to be available prior to randomization  or plasma administration .  
 CBC with differential white ce ll count (to include neutrophil  and lymphocyte percentages), 
hemoglobin, hematocrit, and platelets  
 Blood chemistries (creatinine, glucose, total protein, ALT/GPT, AST/GOT, total bilirubin ) 
 PT/INR 
 
Any tests not collected clinically, should be obtained according to the protocol . Results from laboratory 
tests performed for clinical indicatio ns < 12 hours before randomization  may be used if available.  
[IP_ADDRESS].1 Pediatric Blood Collection Guidelines  
Refer to institutional policies and recommendations on safe blood sample volume limits for pediatric 
patients. Sites may reduce the volume of research blood  sample collection in order to remain within these 
limits. 
[IP_ADDRESS] Baseline Research Procedures on Day [ADDRESS_323351] prior to randomization (no more than 4 hours between collection and 
randomization ).  Baseline research samples should not be collected for screen failures.  
 OP (throat) swab for quantitat ive PCR 
 25.5 mL of blood for adults or 8.5 mL of blood for children should be obtained. This will be used  
for the following laboratory tests:  
 HAI to influenza A/H1N1 and A/H3N2 
 Stored samples for other research tests evaluating the immune response to influ enza as 
defined in Section 7.5 
[IP_ADDRESS] Randomization  
Those subjects found eligible for randomization in this study will be randomized in the IWRS system as 
noted in Section 5.2, after baseline assessments have been completed .  
6.3.4 Study Plasma Administration  
After all baseline evaluations and randomization ha ve been completed, s ubjects will receive the study 
plasma. Refer to Section 5.7 for dosing information. The calendar date and 24 -hour clock time for study 
plasma administration should be recorded for the start and end of each infusion.  
Vital signs should be obtained dur ing plasma infusion according to institutional policies . Vital signs 
during infusion are not collected in the database . All grade 3 or grade 4 AEs (e.g. hypotension) or other 
events (chest pain, rash, etc.) and all SAEs occurring during study plasma admini stration should be 
captured as noted in Section 10.2.  
Protocol IRC00 5  Page 34 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
6.3.5 Study Day 1 
Day 1 is always the calendar day following the day of randomization, even if the plasma infusion starts 
late in the day of randomization or i f the plasma infusion starts on the calendar day following the day of 
randomization . However, plasma administration should be complete d prior to collecting the Day 1 visit 
procedures . 
[IP_ADDRESS] Clinical Data on Day 1  
 Vital signs, including SpO2. These values may be obtained from clinically collected information 
if they were obtained within [ADDRESS_323352] be collected in a 
complete set within 30 minutes of each other.  
 Clinical data 
 Assessment of clinical status (6-point ordinal scale ) 
 Glasgow coma scale  
 Organ dysfunction score  
 SOFA score for age ≥ 18 years 
 PELOD score for age < 18 years 
 Measures of clinical support:  
 Hospi[INVESTIGATOR_059]  
 Oxygen requirement  
 Mechanical ventilator requirement  
 ICU requirement  
 ECMO requirement  
 Chest x-ray finding if performed for clinical indication  
 Assessment of ARDS using PaO 2 (or SpO2), FiO 2, and recent chest x -ray data. 
 Review new medical conditions, co ncomitant  medication, and evaluate for AE s 
[IP_ADDRESS] Clinical Laboratory Tests on Day [ADDRESS_323353] will be performed:  
 CBC with differential white ce ll count (to include neutrophil  and lymphocyte percentages), 
hemoglobin, hematocrit, and platelets  
 Blood chemistries (creatinine, glucose, total protein, ALT/GPT, AST/GOT, total  bilirubin)   
 PT/INR 
Results from laboratory tests performed for clinical indications < 12 hours before the visit may be used if 
available. Any tests not collected clinically, should be obtained according to the protocol.  
[IP_ADDRESS] Research Procedures on Day 1  
The following research procedures will be performed:  
 17 mL of blood for adults or  8.5 mL for children should be obtained. This will be used for the 
following laboratory tests:  
 HAI to influenza A/H1N1 and A/H3N2  
 Stored samples for other research tests evaluating  the immune response to influenza as 
defined in Section 7.[ADDRESS_323354] is no longer hospi[INVESTIGATOR_057], this visit may occur by [CONTACT_756]. In this case, the assessments 
below should be restricted to the ordinal scale , oxygen requirements , new medical conditions, 
concomitant  medication, and evaluation for AEs .  
Protocol IRC00 5  Page 35 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
[IP_ADDRESS] Clinical Data on Day 2 
 Vital signs, including S pO2. These values may be obtained from clinically collected information 
if they were obtained within [ADDRESS_323355] be collected in a 
complete set within 30 minutes of each other.  
 Clinical data 
 Assessment of clinical status (6-point ordinal scale ) 
 Measures of clinical support:  
 Hospi[INVESTIGATOR_059]  
 Oxygen requirement  
 Mechanical ventilator requirement  
 ICU requirement  
 ECMO requirement  
 Chest X-ray finding if performed for clinical indication  
 Assessment of ARDS using PaO 2 (or SpO2), FiO2, and recent chest x -ray data. 
 Review new medical conditions, co ncomitant  medication, and evaluate for AEs  
6.3.[ADDRESS_323356]’s ability to provide consent should be evaluated . Any subject who was unable to previously 
provide consent independently sh ould be administered the informed consent according to institutional 
policies. 
[IP_ADDRESS] Clinical Data on Day [ADDRESS_323357] occur  in the hospi[INVESTIGATOR_7708], or be conducted as a home visit if authorized in accordance 
with Section 6.2. During this visit the following will occur:  
 Vital signs, including S pO2. These values may be obtained from clinically collected information 
if they were obtained within 4 hours of the study assessment.  Vital signs should be collected in a 
complete set within 30 minutes of each other.  
 Clinical data 
 Assessment of clinical status (6-point ordinal scale ) 
 Glasgow coma scale  
 Early warning score  
 NEW score for age ≥ 18 years 
 PEW score for age < 18 years 
 Organ dysfunction score  
 SOFA score for age ≥ 18 years 
 PELOD score for age < 18 years 
 Measures of clinical support:  
 Hospi[INVESTIGATOR_059]  
 Oxygen requirement  
 Mechanical ventilator requirement  
 ICU requirement  
 ECMO requirement  
 Chest x-ray finding if performed for clinical indication  
 Assessment of ARDS using PaO 2 (or SpO2), FiO 2, and recent chest x -ray data. 
 Review new medical conditions, co ncomitant  medication, and evaluate for AE s 
  
Protocol IRC00 5  Page 36 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
[IP_ADDRESS] Clinical Safety Laboratory Tests on Day [ADDRESS_323358] will be performed:  
 CBC with differential white ce ll count (to include neutrophil  and lymphocyte percentages), 
hemoglobin, hematocrit, and platelets  
 Blood chemistries (creatinine, glucose, total protein, ALT/GPT, AST/GOT, total bilirubin)  
 PT/INR 
Results from lab oratory tests performed for clinical indications < 12 hours before the visit  may be used if 
available. Any tests not collected clinically, should be obtained according to the protocol.  
[IP_ADDRESS] Research Procedures on Day 3 
The following research procedures will be performed:  
 OP (throat) swab for quantitative PCR  
 17 mL of blood for adults or 8.5 mL for children  should be obtained. This will be used for the 
following laboratory tests:  
 HAI to influenza A/H1N1 and A/H3N2    
 Stored samples for other research tests evaluat ing the immune response to influenza as 
defined in Section 7.5 
6.3.8 Study Day 7 (±1) 
The subject’s ability to provide consent should be evaluated . Any subject who was un able to previously 
provide consent independently should be administered the informed consent according to institutional 
policies. 
[IP_ADDRESS] Clinical Data on Day [ADDRESS_323359] occur in the hospi[INVESTIGATOR_7708], or be conducted as a home visit if authorized in accordance 
with Section 6.2. During this visit the following will occur:  
 Vital signs, including SpO2. These values may be obtained from clinically collected information 
if they were obtained within 4 hours of the study assessment.  Vital signs should be collected in a 
complete set within 30 minutes of each other.  
 Concomitant medications  
 Clinical data 
 Assessment of clinical status (6-point ordinal scale) 
 Glasgow coma scale  
 Early warning score  
 NEW score for age ≥ 18 years 
 PEW score for age < 18 years 
 Organ dysfunction score  
 SOFA score for age ≥ 18 years 
 PELOD score for age < 18 years 
 Measures of clinical support:  
 Hospi[INVESTIGATOR_059]  
 Oxygen requirement  
 Mechanical ventilator requirement  
 ICU requirement  
 ECMO requirement  
 Chest x-ray finding if performed for clinical indication  
 Assessment of ARDS using PaO 2 (or SpO2), FiO 2, and recent chest x -ray data. 
Protocol IRC00 5  Page 37 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
 Review new medical conditions, co ncomitant  medication, and evaluate for AE s 
[IP_ADDRESS] Clinical Safety Laboratory Tests on Day [ADDRESS_323360] will be performed:  
 CBC with differential white ce ll count (to include neutrophil  and lymphocyte percentages), 
hemoglobin, hematocrit, and platelets  
 Blood chemistries (creatinine, glucose, total protein, ALT/GPT, AST/GOT, total bilirubin)  
 PT/INR 
Results from laboratory tests performed for clinical indications < 24 hours before the visit  may be used if 
available. Any tests not collected clinically, should be obtained according to the protocol.  
[IP_ADDRESS] Research Procedures on Day 7 
The following research procedures will be performed:  
 17 mL of blood for adults or 8.5 mL for children should be obtained. This will be used for the 
following laboratory tests:  
 HAI to influenza A/H1N1 and A/H3N2    
 Stored samples for other research tests evaluating the im mune response to influenza as 
defined in Section 7.5 
[IP_ADDRESS] Day [ADDRESS_323361]  to obtain 
information about their disposition and function al status (in order to score the Day 7 Clinical Status  
[primary endpoint]). If the subject cannot be reached by [CONTACT_648], the hospi[INVESTIGATOR_265886]/when the subject was di scharged, and to determine the clinical status on Day 7.  This miss ed 
visit may still be a protocol deviation, but this would allow the  primary endpoint to be ascertained.  
6.3.9 Study Day 14 (±2) 
If the subject is no longer hospi[INVESTIGATOR_057], this visit may occur by [CONTACT_756]. In this case, the assessments 
below should be restricted to the ordinal scale, oxygen requirements, new medical conditions, 
concomitant  medication, and evaluation for AEs . The subject’s ability to provide consent should be 
evaluated . Any subject who was unable to previously provide consent independently should be 
administered the informed consent according to institutional policies.  
[IP_ADDRESS] Clinical Data on Day 14  
 Vital signs, including SpO2. These values may be obtained from clinically collected information 
if they were obtained within 4 hours of the study assessment.  Vital signs should be collected in a 
complete set within  30 minutes of each other.  
 Clinical data 
 Assessment of clinical status (6-point ordinal scale ) 
 Measures of clinical support:  
 Hospi[INVESTIGATOR_059]  
 Oxygen requirement  
 Mechanical ventilator requirement  
 ICU requirement  
 ECMO requirement  
 Assessment of ARDS using PaO 2 (or SpO2), FiO 2, and recent chest x -ray data. 
 Review new medical conditions, co ncomitant  medication, and evaluate for AE s 
Protocol IRC00 5  Page 38 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
6.3.10 Study Day 28 (Day 28-32) 
If the subject is no longer hospi[INVESTIGATOR_057], this visit may occur by [CONTACT_756]. In this case, the assessments 
below should be restricted to the ordinal scale, oxygen requirements, new medical conditions, 
concomitant  medication, and evaluation for AEs .  
[IP_ADDRESS] Clinical Data on Day 28 
 Vital signs, including S pO2. These values may be obtained from clinically collected information 
if they were obtained within 4 hours of the study assessment.  Vital signs should be collected in a 
complete set within 30 minutes of each othe r. 
 Clinical data 
 Assessment of clinical status (6 -point ordinal scale)  
 Measures of clinical support:  
 Hospi[INVESTIGATOR_059]  
 Oxygen requirement  
 Mechanical ventilator requirement  
 ICU requirement  
 ECMO requirement  
 Assessment of ARDS using PaO 2 (or SpO2), FiO 2, and recent chest x -ray data. 
 Review new medical conditions, co ncomitant  medication, and evaluate for AEs  
6.[ADDRESS_323362] additional follow -up to evaluate outcomes of the pregnancy. Th ese visits 
may occur in the hospi[INVESTIGATOR_307], clinic, by [CONTACT_14716], or by [CONTACT_756], and should occur every month ( ±2 
weeks, by [CONTACT_265940] ) starting one month after discharge until after delivery. The 
purpose is to assess for SAEs and for pregnancy outcom e including gestational age at outcome and live 
births. 
7 MEASURES OF EFFICACY, SAFETY, AND PHARMACOKINETICS  
7.1 Pharmacokinetic Measures  
Anti-influenza A/H1N1  and A/H3N2 antibodies will be measured by [CONTACT_265941] 0 
(pre-infusion), 1, 3, and 7. 
7.[ADDRESS_323363] assessment of a given study day (i.e., at 
approximately 8AM). The clinical status should be recorded as the subject currently exists, without 
consideration as to need (i.e. , is the subject in the ICU, and not does the subject have medical needs to be 
in the ICU, or has the subject been d ischarged home and not is the subject capable at that moment of 
being discharged to home). The scale is as follows:  
1. Death 
2. In ICU 
3. Non-ICU hospi[INVESTIGATOR_059], requiring supplemental oxygen  
4. Non-ICU hospi[INVESTIGATOR_059], not requiring supplemental oxygen  
Protocol IRC00 5  Page 39 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323364] onset of symptom(s) of influenza.  
7.3.2 NEW Score  
The NEW Score  has demonstrated an  ability to discriminate patients at risk of poor outcomes. [15] This 
score is based on 7 clinical parameters. The NEW Score is being used for inclusion criteria, and for 
efficacy (change from baseline to Day 3 and Day 7). For inclusion criteria, the NEW score is used to 
define severe infl uenza.  Therefore , the subject must have had a NEW score ≥  [ADDRESS_323365] assessment of a given study day 
(i.e., at approximately 8AM) . These parameters can be obtained from the hospi[INVESTIGATOR_265887] 4 hours of the time of assessment, or can be meas ured at the time of assessment.  
Table 6: NEW Score  
 
  

Protocol IRC00 5  Page 40 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
7.3.3 PEW Score  
The PEW score is a numerical scoring system to define pediatric patients at risk of clinical deterioration.  
[16] This score is based on 7 clinical parameters. The PEW Score is being used for inclusion criteria, and 
for efficacy (change from baseline to Day 3 and Day 7). For inclusion criteria, the PEW score is used to 
define severe influenza.  Therefore the subject must h ave had a PEW score ≥  [ADDRESS_323366] assessment of a given study day 
(i.e., at approximately 8 :00 AM). These parameters can be obtained from the hospi[INVESTIGATOR_265887] 4 hours of the time of assessment, or can be meas ured at the time of assessment.  
Table 7: PEW Score  
 
7.3.4 SOFA Score  
The SOFA score is a scoring system to determine the extent of a person's organ function or rate of failure. 
[17, 18] The score is based on six different scores, one each for the respi[INVESTIGATOR_696], cardiovascular, hepatic, 
coagulation, renal, and neurological systems.  Baseline assessment should be based on data collected 
closest to (but also prior to)  randomization and plasma administration .  Each subsequent day should use 
the worst value for each parameter in the preceding 24 hour period . 
 
Respi[INVESTIGATOR_265888] 2: 
PaO2/FiO2 (mmHg) 
0 = PaO2/FiO2 ≥ 400 
1 = PaO2/FiO2 < 400 
2 = PaO2/FiO2 < 300 
3 = PaO2/FiO2 < 200 and mechanically ventilated  
4 = PaO2/FiO2 < 100 and mechanically ventilated  
 

Protocol IRC00 5  Page 41 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
PaO2 should be used if available.  However, i f PaO2 is not available, the following table can be used to 
generate the SOFA score with SpO2 [19]:  
Table 8: Use of SpO 2/FiO2 in SOFA Score  
 
 
 
 
 
 
 
 
 
 
 
Note: The original Sp O2/FiO2 Ratio as published would require a S pO2 > 110% to achieve a SOFA  score of 0. 
Therefore, this score has been modified to accept a SpO2 of 96% or greater on room air as normal (i.e. a 
SpO2/FiO2 Ratio of ≥ 457 would be a SOFA score = 0).  
 
Nervous System  
Glasgow coma score  
0 = GCS score of 15 
1 = GCS score of 13-14 
2 = GCS score of 10-12 
3 = GCS score of 6-9 
4 = GCS score of < 6 
 
Cardiovascular System  
Mean arterial pressure  (MAP) OR administration of vasopressors required (vasopressor drug 
doses are in mcg/kg/min)  
0 = No hypotension  
1 = MAP < 70 mmHg  
2 = dopamine ≤ 5 or dobutamine (any dose)  
3 = dopamine > 5 OR epi[INVESTIGATOR_238] ≤ 0.1 OR norepi[INVESTIGATOR_238] ≤ 0.1 
4 = dopamine > 15 OR epi[INVESTIGATOR_238] > 0.1 OR norepi[INVESTIGATOR_238] > 0.1 
 
Liver 
Total Bilirubin (mg/d L) 
0 = Total Bilirubin < 1.2  
1 = Total Bilirubin 1.2 - 1.9 
2 = Total Bilirubin 2.0 - 5.9 
3 = Total Bilirubin 6.0 - 11.9 
4 = Total Bilirubin  ≥ 12.0 
 
  SOFA 
Respi[INVESTIGATOR_265889] 
(using SpO 2)  SpO2/FiO2Ratio 
PEEP < 8 
or not intubated  PEEP 8-12 PEEP > 12 
0 ≥ 457 ≥ 515 ≥ 425 
1 < 457 < 515 < 425 
2 < 370 < 387 < 332 
3 < 240 < 259 < 234 
4 < 115 < 130 < 129 
Protocol IRC00 5  Page 42 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Coagulation  
Platelets×103/µL 
0 = Platelets ≥ 150 ×103/µL 
1 = Platelets < 150 ×103/µL 
2 = Platelets < 100 ×103/µL 
3 = Platelets < 50 ×103/µL 
4 = Platelets < 20 ×103/µL 
 
Renal System  
Creatinine (mg/dL) (or urine output)  
0 = Creatinine  < 1.2 mg/dL 
1 = Creatinine 1.2 - 1.9 mg/dL 
2 = Creatinine 2.0 - 3.4 mg/dL 
3 = Creatinine 3.5 - 4.9 mg/dL, or urine output < 500 mL/d 
4 = Creatinine  ≥ 5.0, or urine output < 200 mL/d, or dialysis requirement  
7.3.[ADDRESS_323367] heart rate of the day was 200 beats/min (10 PELOD points) and systolic blood 
pressure remained at 30 mmHg (20 PELOD points), then 20 PELOD points were assigned. The maximum 
number of points for an organ is 20, and the maximum PELOD score 71 [20, 21]. Baseline assessment 
should be based on data collected closest to (but also prior to)  randomization and plasma administration .  
Each subsequent day should use the worst value for each parameter in the preceding 24 hour period . 
Special Considerations for Respi[INVESTIGATOR_265890]: 
 If blood gas testing was not performed for clinical reasons (e.g., as part of medical care) and the 
subject is not intubated, it can be assumed that the PaO 2/FiO2 ratio is >70 and PaCO 2 is ≤ 90, and 
the respi[INVESTIGATOR_265891] 0 . 
 If the subject is intubated then there will likely be, as part of routine care, an ABG or VBG to 
determine if the score is 1 or 10  points.  
o A PaO 2/FiO2 ratio is ≤ 70 and PaCO 2 is > 90 is very severe disease.  If no ABG or VBG is 
available, the clinical team will be able to estimate if the PaO 2/FiO2 ratio is ≤ 70 or 
PaCO 2 is > 90 based on severity of disea se, in which case  the respi[INVESTIGATOR_265892] 
10.  
 
Protocol IRC00 5  Page 43 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Table 9: PELOD Scoring System  
 
  
0 1 10 20
Neurological*
Glasgow coma s core 12–15 7–11 4–6 3
and or
Pupi[INVESTIGATOR_265893]†
Heart rate (beats/min)
<12 ye ars ≤195 NA >195 NA
≥12 ye ars ≤150 NA >150 NA
and or
Systolic blood pressure 
(mm H g)
<1 mon th >65 NA 35–65 <35
1 mon th−1 year‡ >75 NA 35–75 <35
1–12 ye ars‡ >85 NA 45–85 <45
≥12 ye ars >95 NA 55–95 <55
Renal
Creatinine (mg/ dl)
<7 days <1.58 NA ≥1.58 NA
7 days−1 year‡ <0.39 NA ≥0.39 NA
1–12 ye ars‡ <1.13 NA ≥1.13 NA
≥12 ye ars <1.58 NA ≥1.58 NA
Respi[INVESTIGATOR_696]§
PaO2 (mmH g)/FIO2 ratio >70 NA ≤70 NA
and or
PaCO2 (mmH g) ≤90 NA >90 NA
and
Mechanical ventilation§No ventilationVentilation NA NA
Hematol ogical
White blood cell count 
(×109/L) ≥4.5 1.5–4.4 <1.5 NA
and or
Platelets (×109/L) ≥35 <35 NA NA
Hepatic
Aspartate transaminase 
(IU/L) <950 ≥950 NA NA
and or
Prothromb in time (or INR) >60 ≤60 NA NA
(<1.40) (≥1.40)
Notes:
PaO2=arterial oxygen pressure. FIO2=fraction of inspi[INVESTIGATOR_265894]. 
PaCO 2 =arterial carbon dioxide pressure. INR=international normalized ratio.
† Heart rate and systolic blood pr essure: do n ot assess during crying or iatrogenic agitation.
‡ Strictly less than.* Glasgow c oma score: use lowest value. If patient is sedated, record estimated Glasgow c oma score before 
sedation. Assess patient only with known or suspected acute central nervous system disease. Scoring system
§ If arterial measurement of P aO2 unavailable, estimate fPaO2/FIO2 ration from SaO2.  M echanical 
ventilation: the use of m ask ventilation is not counted as mechanical ventilation.measurement only. PaCO 2 may 
be measured from arterial, capi[INVESTIGATOR_1396], or venous samples.Organ dysfunction and variable
P r o t o c o l  I R C 0 0 5  P a g e  4 4  o f  6 4   
I N D  1 4 2 2 9  C O N F I D E N T I A L  1 5 J U N 2 0 1 7 ;  V e r s i o n  3 . 0  
 
7 . 3 . 6  A R D S  
T h e  i n c i d e n c e  o f  A R D S  w i l l  b e  a s s e s s e d  a t  e a c h  s t u d y  d a y  u s i n g  t h e  r e v i s e d  B e r l i n  de f i n i t i o n  o f  A R D S .  
[2 2 ] 
 
T a b l e  1 0 :  B e r l i n  C r i t e r i a  f o r  A R D S  
 
 
I f  P a O 2 i s  n o t  a v a i l a b l e ,  t h e  M a n u a l  o f  O p e r a t i o n s  (M O P )  p r o v i d e s  i n s t r u c t i o n s  f o r  e s t im a t i n g  t h e  
Pa O 2/ F i O 2 r a t i o  f r om  t h e  F i O2 a n d  S p O2.  
 
T h e  o x y g e n a t i o n  a s s e s sm e n t  s h o u l d  b e  w i t h i n  4 h o u r s  o f  t h e  a s s e s sm e n t  o f  A R D S .  I f  t h e r e  i s  n o  c h e s t  
im a g i n g  o n  t h e  d a y  o f a s s e s sm e n t ,  t h e  m o s t  r e c e n t  im a g i n g  m a y  b e  u s e d .  S u b j e c t s  m e e t i n g  a l l  c r i t e r i a  
m e e t  c r i t e r i a  f o r  A R D S .  S e v e r i t y  s h o u l d  b e  g r a d e d  b a s e d  o n  t h e  o x y g e n a t i o n  i n  t h e  a b o v e  t a b l e .  
7 . 3 . 7  M e a s u r e s  o f  c l i n i c a l  s u p p o r t  
A t  e a c h  s t u d y  d a y ,  t h e  f o l l o w i n g  m e a s u r e  o f  c l i n i c a l  s u p p o r t  s h o u l d  b e  a s s e s s e d :  
 H o s p i t a l i z a t i o n  
 O x y g e n  r e q u i r em e n t  
 M e c h a n i c a l  v e n t i l a t o r  r e q u i r em e n t  
 I C U  r e q u i r em e n t  
 E CM O  r e q u i r em e n t  
 
I f  a n y  o f  t h e s e  a r e  p r e s e n t , i t  s h o u l d  b e  d e t e rm i n e d  i f  t h e s e  a r e  n ew  o r  o n g o i n g  f r om  p r e v i o u s  s t u d y  v i s i t s .  
I n  t h e  c a s e  o f  a  n e w  r e q u i r em e n t ,  t h e  d a t e  s t a r t e d  s h o u l d  b e  r e c o r d e d  ( n o t  j u s t  t h e  d a t e  o f  a s s e s sm e n t ) . 
 
I f  t h e r e  w e r e  p r e v i o u s  i n t e r v e n t i o n s  t h a t  a r e  n o  l o n g e r  n e e d e d ,  t h e  d a t e  o f  d i s c o n t i n u a t i o n  s h o u l d  b e  n o t e d  
( n o t  j u s t  t h e  d a t e  o f  a s s e s sm e n t ) .   
7 . 3 . 8  E f f i c a c y  M e a s u r e s  No t  Us e d  
I n  I R C 0 0 2 ,  s ym p t om  r e s o l u t i o n  p r o v i d e d  n o  d i s c r im i n a t i n g  p o w e r  i n  t h i s  p o p u l a t i o n .  A d d i t i o n a l l y ,  i t  i s  
n o t o r i o u s l y  i n a c c u r a t e ,  a n d  t h e r e f o r e  w i l l  n o t  b e  c o l l e c t e d  i n  t h i s  s t u d y .  M o s t  s u b j e c t s  i n  I R C 0 0 2  d i d  n o t  
h a v e  f e v e r ,  a n d  t h e r e f o r e  r e s o l u t i o n  o f  f e v e r  w i l l  n o t  b e  u s e d  i n  t h i s  s t u d y .  
Protocol IRC00 5  Page 45 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323368] (low -titer) plasma.  
7.4.1 Laboratory Evaluations  
All laboratory evaluations (except reference endpoint assays) will be performed at the local CLIA , CLIP, 
or CAP certified clinical laboratory  (comparable certifications t hat are not listed maybe be used after 
approval by [CONTACT_456]) . The same laboratory should be used throughout the study for a given subject. 
Blood samples will be collected at screening if necessary for ABO typi[INVESTIGATOR_265895], and on 
Study Days 0 , 1, 3, and 7, for evaluation of routine laboratory safety (chemistry, complete blood count 
with differential). The investigator is to use the “Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events” Version 2.0, November 201 4 which can be found in Appendix A .  
7.5 Research Tests  
At visits noted in Section 6, blood will be obtained for other laboratory tests that help characterize 
subjects’ immune response to influenza. This could include antibody response to influenza and other 
biomarkers of severity of disease. Additionally, OP swabs are obtained for the pu rpose of assessing viral 
replication, and any remaining samples may be used to assess other aspect of the virus infection (such as 
sequencing).  No genetic testing of the subject is done on these samples. Any use of these specimens 
beyond the above stated purposes will require review of the planned research by [CONTACT_1201]/IEC.  
8 RISKS/BENEFITS  
8.1 Potential Risks  
8.1.1 Risk of Plasma Transfusions  
Possible transfusion reactions and adverse events are outlined below . The management of all reactions to 
plasma should follow institutional policies and clinician’s judgement .  
 
Common risks of plasma transfusions may include one or more of the following: fever, rash, hives, or 
headache.  
 
Allergic transfusion reactions can occur when patients have antibodies that react with proteins in the 
plasma. They can present with urticaria,  itching, and/or fevers that occur soon after  starting a transfusion . 
Symptoms are usually controlled by [CONTACT_265942]. Generally, the 
transfusion may be continued if the  symptoms are self -limited.  
 
TRALI may occur, but this risk is minimized by [CONTACT_265943] -donated plasma in this study  (as noted 
in Section  5.1). TRALI is characterized by a clinical constellation of symptoms including dyspnea, 
hypotension , and fever. Although the precise pathogenesis of TRALI remains unknown, it has been 
shown to be related to the transfusion of anti -HLA class I and anti -neutrophil ant ibodies most often from 
plasma from multiparous women (antibodies presumably generated during pregnancy) or donors who 
have received multiple blood transfusions. The risk of TRALI is reported as 1 out of 5000 transfusions. 
[23] 
 
The infused plasma volume is roughly 450-700 mL, so there is the risk of volume overload in the 
recipi[INVESTIGATOR_265896]. Transfusion -associated circulatory overload (TACO) has 
Protocol IRC00 5  Page 46 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
been associated with plasma infusion and may be clinically indistinguishable from TRALI even though 
the physiologic mechanisms differ . TACO is hydrostatic not permeability edema and more responsive to 
diuresis when it occurs.  [24] Subjects with preexisting conditions who may not tolerate this volume of 
plasma will be excluded from this study, but this condition cou ld still occur in recipi[INVESTIGATOR_840].  
There are case reports of pulmonary emboli occurring after administration of IVIG and plasma therapy, 
though definitive studies assessing risk are lacking. [25] In one series , [ADDRESS_323369] pulmonary emboli. [26] This high percentage has not been shown in other 
H1N1 series, and pulmonary emboli have been shown to develop in approximately 10 %-15% of critically 
ill adults. [27] However, the potential risk of pulmonary embolism exists.   
In IRC002, one SAE of liver injury was considered  to be possibly related to the plasma administration.  
Acute liver injury has been observed in other subjects and considered not related to the plasma.  In 
IRC005, one SAE of stroke was  considered  to be possibly related to the plasma administration.  Strokes 
were seen at a similar frequency in both the plasma and the control arm o f IRC002 (where no plasma was 
given) and were not considered related to study plasma  in that study .  Given the severity of illness in the 
population  being treated , exact attributio n of causality  of these events  is difficult.  
Other more serious risks are rare and may include the following: serious allergic reactions including 
anaphylaxis , bacterial infections, or viral infections like hepatitis B, hepatitis C, human 
immunodeficiency  virus (HIV) and Zika. Anaphylaxis , which can be life threatening, may be associated 
with skin reactions, swelling of face, lips, tongue or throat, constricted airways with wheezing and trouble 
breathing, weak and rapid pulse, nausea, vomiting, dizziness, fainting and/or shock.  
Protocol IRC00 5  Page 47 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
In IRC002, the study population was very ill and therefore had many Serious Adverse Events (SAEs). 
The following are the list of SAE s seen in IRC002:  
Table 11:  SAEs seen in IRC002  
 

Protocol IRC00 5  Page 48 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323370] will be asked  about participation in other research studies to ensure that 
blood draws do not exceed the following amounts for all research protocols combined: 10.5 mL/kg or 550 
mL, whichever is smaller, over any 8 -week period for adults, and no more than 5 mL/kg in a single day 
(no more than 9.5 mL/kg may be drawn over any 8 -week period) for persons under the age of 18.  
8.1.[ADDRESS_323371] antiviral therapy (i.e., oseltamivir) will more rapi[INVESTIGATOR_265897] -influenza plasma.  
8.2.2 Benefits of Diagno sis  
Knowing the diagnosis of influenza will allow appropriate precautions to be taken to prevent accidental 
transmission and infection to others (i.e ., family members, co -workers, etc.). This knowledge may also 
allow appropriate public health intervention s to possibly minimize additional cases.  
8.2.[ADDRESS_323372] care. For suspected or confirmed severe 
influenza this will generally include an antiviral (amantadine, rimantadine, oseltamivir, or z anamivir) 
determined largely on availability and susceptibility.  
9 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS AND DATA  
9.1 Intended Use of the Samples/Specimens/Data  
Samples and data collected under this protocol may be used to study the clinical features, immunology, 
and virology of human influenza.  
9.2 Storage of Samples/Specimens/Data  
As part of this protocol, and with consent from study subjects, samples will be stored for further research. 
Any future research (aside from research listed within this protoco l) will require approval from the 
IRB/EC. Samples and data will be stored using codes assigned by [CONTACT_165106](s). 
Data will be kept in password -protected computers which are located in locked rooms. Samples will be 
stored in locked facilities.  
9.3 Storage of Genetic Sample  
Samples will not be obtained or stored for genetic testing as part of this study .  
Protocol IRC00 5  Page 49 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
9.4 Tracking Samples/Specimens/Data  
Samples will be tracked by a commercial software program.  
9.5 Use of Samples/Specimens/Data at the Completion of the Protocol  
Samples will be maintained for further laboratory testing  for up to 10 years after completion (or 
termination) of the protocol.  This length of time for storing samples may be extended only after 
permission of the IRB/IEC.   
9.6 Reporting Loss or Destruction of Samples/Specimens/Data  
Any loss or unanticipated destruction of locally maintained samples (for example, due to freezer 
malfunction) or data (for example, misplacing a printout of data with identifiers) will be reported to the 
corresponding IRB/IECs.  
Any loss or unanticipated destruction of centrally maintained samples or data will be reported to all 
IRB/IECs.   
10 ASSESSMENT OF SAFETY  
10.1 Definitions  
Adverse Event (AE)  
An AE is any untoward or unfavorable medical occurrence in a human subject, including any abnormal 
sign (e.g., abnormal physical exam or laboratory finding), symptom, or disease, temporally associated 
with the subject’s participation in the research, whether or not considered related to the research.  
Adverse Reaction (AR)  
An AE that is caused by [CONTACT_4523] (drug or biologic).  
Suspected Adverse Reaction (SAR)  
An AE for which there is a reasonable possibility that the investigational agent caused the AE. 
‘Reasonable possibility’ means that there is evide nce to suggest a causal relationship between the drug 
and the AE. An SAR implies a lesser degree of certainty about causality than AR, which implies a high 
degree of certainty.  
Serious Adverse Event (SAE)  
An SAE is an AE that results in one or more of the following outcomes:  
 death  
 a life threatening event (places the subject at immediate risk of death from the event as it 
occurred)  
 an inpatient hospi[INVESTIGATOR_1324]   
 a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions  
 a congenital anomaly/birth defect  
 a medically important event *  
 
* Medical and scientific judgment should be exercised in deciding events t hat may not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_265898] . 
Protocol IRC00 5  Page 50 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Unexpected Adverse Event  
An AE is unexpected if it is not liste d in the Investigator’s Brochure or is not listed at the specificity or 
severity that has been observed.  
It is the responsibility of the IND Sponsor to make this determination.  
Serious and Unexpected Suspected Adverse Reaction (S[LOCATION_003]R)  
A S[LOCATION_003]R is a n SAR that is both serious and unexpected .  
Unanticipated Problem (UP)  
A UP is any event, incident, experience, or outcome that is :  
1. unexpected in terms of nature, severity, or frequency in relation to  
a. the research risks that are described in the IRB-approved research protocol and informed 
consent document , Investigator’s Brochure , or other study documents; and  
b. the characteristics of the subject population being studied; and  
2. possibly , probably, or definitely related to participation in the research; and  
3. places subjects or others at a greater risk of harm (including physical, psychological, economic, or 
social harm) than was previously known or recognized. (Per the IND Sponsor, an AE with a serious 
outcome will be considered increased risk.)  
 
Unanticipated Problem that is not an Adverse Event (UPnonAE)  
A UP that does not fit the definition of an AE, but which may, in the opi[INVESTIGATOR_871], involve 
risk to the subject, af fect others in the research study, or significantly impact the integrity of research data. 
Such events would be considered non -serious UP s. For example, we will report occurrences of breaches 
of confidentiality, accidental destruction of study records, or unaccounted -for study drug.  
Protocol Deviation  
Any change, divergence, or departure from the IRB -approved study procedures in a research protocol. 
Protocol deviations are designated as serious or non -serious and further characterized as :  
1. Those that o ccur because a member of the research team deviates from the protocol;  
2. Those that are identified before they occur, but cannot be prevented;  
3. Those that are discovered after they occur.  
Serious Protocol Deviation  
A deviation that meets the definit ion of a SAE or compromises (or has the potential to compromise) the 
safety, welfare , or rights of subjects or others.  
10.2 Documenting, Recording, and Reporting  Adverse Events  
All grade 3 or grade 4  AEs, and all SAEs occurring from the time the informed consent is signed through 
the Day 28 (end of study) visit will be documented, recorded, and reported.   Additionally, any AE leading 
to plasma discontinuation (regardless of grade) will be documented, recorded, and repo rted.   
At each contact [CONTACT_1155], information regarding AEs will be elicited by [CONTACT_40736]:  
 immediately documented in the subject’s medical record/source document,  
 recorded on the AE eCase Report Form (AE eCRF), and 
 reported as outlined below .  
If a diagnosis is clinically evident (or subsequently determined), the diagnosis rather than the individual 
signs and symptoms or lab abnormalities will be recorded as the AE.  
Protocol IRC00 5  Page 51 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
All abnormal laboratory findings will be reviewed on a routine basis by [CONTACT_978] [INVESTIGATOR_265899]. All worsening laboratory values should be evaluated as potential AEs: 
 If an abnormal laboratory finding is captured as a component of a dia gnosis AE term that has 
already been recorded, the individual abnormal laboratory finding is NOT recorded as a separate 
AE. 
 A laboratory abnormality should be reported as an AE if it requires an intervention  or is 
considered clinically significant by [CONTACT_941] i nvestigator  (all Grade 3 or higher  are considered 
clinically significant for this study ). Interventions include, but are not limited to, discontinuation 
of treatment, dose reduction/dela y, additional assessments  such as repeating the lab test , or 
concomitant treatment.   
An abnormal lab not included on the DAIDS Table for Grading the Severity of Adult and Pediatric 
Events (V.2.0, Nov, 2014)  should be assessed based on the following grading  criteria. 
 Grade 1 (Mild) [not reportable]  
Events causing no or minimal interference with daily activity  
 Grade 2 (Moderate)  [not reportable]  
Events causing greater than minimal interference with daily activity but not requiring medical 
intervention  
 Grade 3 (Severe)  [reportable]  
Events causing inability to perform daily activity, or suggests organ toxicity, and/or requires 
medical intervention  
 Grade 4 (Potentially Life -Threatening)*  [reportable]  
Events causing inability to perform basic self -care functions OR medical or operative 
intervention indicated to prevent pe rmanent impairment, persistent disability, or death  
 Grade 5 (Death)  [reportable]  
 
* Note:  A severity assessment of “p otentially life -threatening” is not necessarily the same as  a 
life-threatening event as described in the SAE criterion. The latter means that the event is an 
immediate threat to life as opposed to a potential threat to life.  
 In addition, any medically important laboratory abnormality may be reported as an AE at the 
discretion of the investigator who considers the test result clinically sign ificant. This could 
include a laboratory result for which there is no intervention but the abnormal value is of clinical 
concern or suggests disease or organ toxicity. Grading should be based on the toxicity table where 
applicable  or per the above guidelin es. 
10.2.1 Assessment of Adverse Event  
The Investigator (or designee) will evaluate all AEs with respect to Seriousness ( SAE criteria listed 
above), Severity (grading), and Causality (relationship to study agent and relationship to research)  
according to the following guidelines.  
10.2.2 Severity 
The Investigator (or designee) will grade the severity of each AE according to the “Division of AIDS 
Table for Grading the Severity of Adult and Pediatric Adverse Events” Version 2.0, November 2014 
which can be found in Appendix A . 
Protocol IRC00 5  Page 52 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
10.2.3 Causality  
Causality (likelihood that the event is caused by [CONTACT_4526](s)) will be assessed considering the 
factors listed under the following categories:  
Definitely Related  
 reasonable tempo ral relationship  
 follows a known response pattern  
 evidence to suggest a causal relationship  
 is no alternative etiology  
 
Probably Related  
 reasonable temporal relationship  
 follows a suspected response pattern (based on similar agents)  
 no evidence of a more l ikely alternative etiology  
 
Possibly Related  
 reasonable temporal relationship  
 little evidence for a more likely alternative etiology  
 
Unlikely Related  
 does not have a reasonable temporal relationship  
OR 
 good evidence for a more likely alternative etiology  
 
Not Related  
 does not have a temporal relationship  
OR 
 definitely due to an alternative etiology  
 
Note: Other factors should also be considered for each causality category when appropriate.  
Causality assessment is based on available information at the time of the assessment of the AE.  
The investigator (or designee) may revise the causality assessment as additional information becomes 
available.  
10.3 Investigator Reporting Responsibilities to the Sponsor  
10.3.1 Adverse Events  
Line listings and/or cumulative listings of A Es will be generated from the centralized database and 
submitted to the Sponsor when needed for  periodic safety assessments, review of IND safety reports , 
preparation of IND annual reports and final study reports . 
Protocol IRC00 5  Page 53 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
10.3.2  Serious Adverse Events  
All SAEs (regardless of relationship and whether or not they are also UPs) must be reported on the Safety 
Expedited Report Form (SERF) and sent to the Clinical Safety Office (CSO) by [CONTACT_265944]. 
Deaths and immediately life threatening SAEs mus t be reported to the CSO within [ADDRESS_323373] INFORMATION:  
Clinical Safety Office  
[ADDRESS_323374]  
Frederick, MD [ZIP_CODE]  
Phone 301 -846-5301  
Fax [PHONE_016]  
E-mail: [EMAIL_007]   
 
SAEs that have not resolved by [CONTACT_1008] -up period are followed until final outcome is 
known. If it is not possible to obta in a final outcome for an SAE (e.g., the subject is lost to follow -up), the 
reason a final outcome could not be obtained will be recorded by [CONTACT_265945]. 
10.3.[ADDRESS_323375] be reported to the CSO and sent by [CONTACT_265946] 7 
calendar days of site awareness of the event. UPs that are related to plasma administrati on, regardless of 
whether an AE occurred or not, should be reported  to the CSO.  All other UPs that are not  associated with 
an AE are not reported to the CSO  but may require sponsor and IRB notification . 
If reporting  UPs to the CSO , use the SERF or a local IRB UP form.  
10.4 Safety Reporting for Off Study Subjects 
After the end of the protocol -defined AE reporting pe riod (Consent through the Day 28 visit), SAEs that 
are thought possibly, probably  or definitely related to the plasma  should be reported as SAE s if the site 
becomes aware of the event . However, aside from pregnancy follow -up detailed in Section 6.4, there is no 
expectation to actively evaluate all subjects for SAEs after protocol -defined AE reporting period ends.  
Any SAEs that occur after the Day 28 visit will be noted in the final study report , though will not be used 
for the primary efficacy and safety analysis.  
10.5 Investigator Reporting Responsibilities to the IRB  
Investigators are responsible for reporting per their local IRB’s requirements. The IRB -specific reporting 
requirements are attached as an append ix [if applicable].  
10.6 Sponsor’s Reporting Responsibilities  
S[LOCATION_003]Rs as defined in 21 CFR 312.32 and determined by [CONTACT_40741].  
The IND Sponsor will also submit an IND Annual  Report of the progress of the investigation to the FDA 
as defined in 21 CFR 312.33.  
AEs that are also UPs will be summarized by [CONTACT_265947].  
Protocol IRC00 5  Page 54 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
10.7 Safety Oversight  
10.7.1 Protocol Team Monitoring Plan  
The protocol team will  review the enrollment and study -related safety data (AEs and SAEs) from all sites 
periodically during the study. These reviews will occur at a minimum twice monthly during active 
enrollment and follow -up. During perio ds of low influenza activity when no enrollment is occurring, 
these reviews do not need to occur.  
10.7.2 Sponsor Medical Monitor  
A Medical Monitor, representing the IND Sponsor (OCRPRO), has been appointed for oversight of safety 
in this clinical study. The S ponsor Medical Monitor will be responsible for performing periodic safety 
assessments .  
10.[ADDRESS_323376] . Given the seasonal nature of influenza (generally November through April) 
the interim reviews  will occur after each influenza season . The Board may convene additional reviews as 
necessary. The Board will review the study data to evaluate the safety, efficacy, study progress, and 
conduct of the study. All SAEs, all  UPs, and all IND Safety Reports will be reported to the DSMB by [CONTACT_265948]. The DSMB will be notified of any cases of intentional or unintentional unblinding as soon as 
possible.  
As a guideline for monitoring results comparing randomized treatments for the primary endpoint, as it is 
unlikely that this trial will be replicated, a high level of evidence concerning any favorable effect of high -
titer versus low -titer anti-influenza plasma is considered desirable before considering early termination of 
the study.  For this reason, the Peto -Haybittle stoppi[INVESTIGATOR_105439]; this requires a nominal p -
value of < 0.[ADDRESS_323377] in comparing mortality rates between randomized arms, then termination of the  
study might also be considered.  
If accrual is slower than anticipated such that the study is not fully enrolled within three years, then a 
futility analysis may be conducted at that time (i.e. after about three years of enrollment) . The DSMB may 
recommend  termination or modification of the study if it appears unlikely that continuation of the study 
will demonstrate a benefit of high titer plasma on the primary endpoint . Conditional power provides a 
measure for evaluating futility : specifically, conditional  on the results observed at an interim analysis, it is 
the power of the study to show a significant benefit of high titer plasma  assuming an underlying true 
difference between the randomized arms (that will determine what future data might be observed) . 
Conditional power will be evaluated both (a) under the assumption that high titer plasma truly affects the 
primary endpoint by [CONTACT_265949] (providing 90% power —see Section 
1.2); and (b) for a range of true effects that appear plausible based on the observed rates at the time of the 
interim analysis.  
Consideration of futility with respect to conditional power requires consideration by [CONTACT_265950] . For example, this might be because of effects 
being observed on mortality or other secondary endpoints or because continuing the study might be 
valuable in showing definitively a lack of an effect of high titer versus low titer plasma . As guidance, 
Protocol IRC00 5  Page 55 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323378] of high versus low titer plasma i f the study continued 
to its planned sample size is lower than 20% under a range of plausible situations covered by (a) and/or 
(b) above, then the DSMB might recommen d study termination.  
Each site PI [INVESTIGATOR_265900](s).  
10.[ADDRESS_323379] many SAE s due to the underlyin g illness. The medical monitor’s review of the safety data is 
most likely to detect signals suggesting subject safety is compromised . However, below are absolute 
criteria for which the study will be paused  to further enrollment  until assessed by [CONTACT_265951]: 
 Two or more of the same  unexpected  SAE (unexpected AE in terms of previously described risks  
in the Investigator’s Brochure ) that are probably or definitively attributed to the study plasma. 
 Four or more of the same  SAE that can be possibly, probably, or definitively attributed to the study 
drug. 
The sponsor medical monitor will ultimately make the decision to either resume the study, ask for formal 
DSMB review, or stop the study.  
11 STUDY MONITORING  
As per ICH -GCP 5.18  and FDA 21 CFR 312.50, clinical protocols are required to be adequately 
monitored by [CONTACT_4530]. This study monitoring will be conducted according to the “NIAID 
Intramural Clinical Monitoring Guidelines.” Monitors under contract to the NIAID will v isit the clinical 
research site to monitor all aspects of the study in accordance with the appropriate regulations. The 
objectives of a monitoring visit will be:  
1) to verify the existence of signed informed consent documents and documentation of the informed 
consent process for each monitored subject ; 
2) to verify the prompt and accurate recording of all monitored data points, and prompt reporting of 
all SAEs; 
3) to compare abstracted information with individual subjects’ records and source documents 
(subjects’ charts, laboratory analyses and test results, physicians’ progress notes, nurses’ notes, and 
any other relevant original subject information); and  
4) to help ensure investigators are in compliance with the protocol.  
The monitors also will inspect the clinical site regulatory files to ensure that regulatory requirements 
(Office for Human Research Protections -OHRP), FDA, and applicable guidelines (ICH -GCP) are being 
followed. During the monitoring visits, the investigator (and/or designee) and other study personnel will 
be available to discuss the study progress and monitoring visit.  
The site investigator  (and/or designee) will make study documents (e.g., consent forms) and pertinent 
hospi[INVESTIGATOR_43561], the U.S. FDA, the site 
monitors, and the NIAID staff for confirmation of the study data.  
[ADDRESS_323380] the 
Protocol IRC00 5  Page 56 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323381] 
subjects that do not receive plasma withdraw from the study early (Day 0 -2 based in IRC002 data) . 
Therefore, use of the modified intention-to-treat population  is thought reasonable for this study . 
Supplementary intention -to-treat analyses including all randomized subjects for mortality, primary 
endpoint, and main secondar y endpoints will be provided in the final analysis , though there may be 
limited follow-up data on many of the subjects who d id not receive plasma . 
12.2 Sample Size and Power Considerations  
The planned sample size for the trial is 150 subjects , randomized in an approximately 2:1 ratio to high -
titer versus low -titer anti-influenza plasma . To evaluate the power of the study, the following assumptions 
were made:  
a. The primary analysis will compare the high -titer and low-titer plasmas using a proportional odds 
model and a  two-sided Type I error rate of 0.05 .  
 
b. It is anticipated that very few of these subjects will be randomized and not start study plasma 
infusion (and so be excluded from the primary analysis) or be lost to follow -up prior to Day 7 
(and so have missing data for the primary endpoint). In addition,  power is reduced slightly and 
hence the effective sample size is reduced by [CONTACT_265952]. 
Conservativel y, a 10% reduction in the total sample size from 150 to 135 subjects was made to 
allow for these issues .  
 
c. Data from the contro l arm of IRC002 for adults with influenza A infection, NEW score ≥ 3, and 
duration of time from onset of symptoms of influenza to randomization ≤ 6 days, suggests the  
distribution of subjects in the low -titer arm for the primary endpoint  shown in the follo wing table:  
 
Table 12: Anticipated Distribution of Subjects in the Ordinal Scale   
 Low-Titer 
Arm High-Titer Arm  
 (Based on IRC 
002) 80% Power  90% Power  
Died 10% 4.3% 3.7% 
In ICU 35% 20.4% 18.4% 
Non-ICU hospi[INVESTIGATOR_059], 
requiring supplemental oxygen   25% 23.6% 22.6% 
Non-ICU hospi[INVESTIGATOR_059], not 
requiring supplemental oxygen  10% 13.3% 13.4% 
Not hospi[INVESTIGATOR_057], but unable to 
resume normal activities  5% 7.9% 8.2% 
Not hospi[INVESTIGATOR_057], but with full 
resumption of normal activities  15% 30.6% 33.7% 
Proportional odds ratio 
comparing high titer to low titer   2.50 2.88 
Protocol IRC00 5  Page 57 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Based on the above assumptions, the table also shows the type of true difference (assuming proportional 
odds) that would be detected with 80% or 90% power.  For example, the study would have 80% power to 
detect a proportional odds ratio of 2.50. This is the odds ratio that arises when comparing  the proportion 
not hospi[INVESTIGATOR_265901] -titer arm (30.6%) to that in the low -titer 
arm (15%).  The proportional odds model assumes that the same odds ratio applies to the cumulative 
proportions moving up the ordinal scale: for example, for the proportion not hospi[INVESTIGATOR_265902] -titer 
arm (30.6+7.9=38.5%) to that in the low -titer arm (15+5=20%) ; or for the proportion alive and not in an 
ICU in the high -titer arm (30.6+7.9+13.3+23.6=75.4%) to that in the low -titer arm (15+5+10+25=55%) .  
12.[ADDRESS_323382] an infusion of study plasma started. Statistical inferences will use a 
two-sided Type 1 error rate of 0.05, and corresponding 95% confidence intervals.  
Analysis of the primary endpoint (ordinal outcome of clinical status at Day 7) will use a proportional odds 
model with an indicator variable for randomized treatment. It is useful to note that the score test of the 
treatment effect from a proportional odds model is  equivalent to a Wilcoxon rank sum test even if the 
proportional odds assumption does not hold . If there are missing data for th e primary endpoint , then 
sensitivity analyses will be undertaken to evaluate the sensitivity of study conclusions to the handlin g of 
the missing data. The proportional odds model will be extended to undertake comparisons of randomized 
treatments adjusted for variables that might be predictive of the outcome, for example, the ordinal clinical 
status at baseline. The model will also be extended to evaluate possible differences  in the comparison of 
randomized treatments b etween subgroups of subjects (treatment by [CONTACT_226418]) , including 
subgroups defined by [CONTACT_4321], age (adult/child), race/ethnicity, ordinal clinical status at bas eline, NEW score 
at baseline, and days since onset of influenza symptoms to randomization.  
Binary variables such as [ADDRESS_323383] to censoring (e .g., for 
subjects in an ICU on Day 28); these will be compared between randomized arms using non -parametric 
tests (e.g., Wilcoxon’s Test adapted, if necessary, to handle censoring).  
Analysis of AE data will primarily be descriptive based on MedDRA coding of events. The propo rtion of 
subjects experiencing an SAE and the proportion experiencing a Grade 3 or higher AE will be compared 
between randomized arms using Fisher’s Exact Test.  
Analysis of HAI titers will also primarily be descriptive, comparing the geometric mean titers at Days 0, 
3, and 7 between randomized arms, to confirm (or otherwise) a difference in titers for subjects receiving 
high-titer versus low -titer anti-influenza plasma .  
For enrolled subjects who were not randomized (i.e. screen failures) or who were random ized but did not 
receive plasma , the final analysis will detail safety (deaths and SAEs), and reasons they were n ot 
randomized or did not received plasma  respectively.  
Protocol IRC00 5  Page 58 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323384] ’s clinical status at Da y 7 (6-point ordinal scale ): 
1. Death 
2. In ICU 
3. Non-ICU hospi[INVESTIGATOR_059], requiring supplemental oxygen  
4. Non-ICU hospi[INVESTIGATOR_059], not requiring supplemental oxygen  
5. Not hospi[INVESTIGATOR_057], but unable to resume normal activities  
6. Not hospi[INVESTIGATOR_52091]  
12.4.2 Secondary Endpoints  
 Ordinal outcome assessed at Days 1, 2, 3, 7, 14 , and 28 
 Date of hospi[INVESTIGATOR_135736]  
 Date and cause of death (if applicable)  
 NEW/PEW score at Day 0, 3 , and 7 
 Date/time of supplemental oxygen initiation and discontinuation (if applicable)  
 Date/time of ICU admission and discharge (if applicable)  
 Date/time of mechanical ventilation initiation and discontinuation (if applicable)  
 Date/time of meeting ARDS criteria, date of r esolution, and severity  (if applicable)  
 Date/time of ECMO initiation and discontinuation (if applicable)  
 SOFA score for age ≥ 18 years and PELOD score for age < 18 years on Days 0, 3, 
and 7 
 Disposition (home, rehabilitation, chronic nursing facility) following the initial 
hospi[INVESTIGATOR_059]  
 Quantitative PCR for influenza in oral swab on Day 0 and 3.  
 Grade 3 and 4 adverse events  
 SAEs 
 Safety laboratory tests will be collected on Day s 0, 1, 3, and 7  
o CBC with differential white cell count (to include neutrop hil and lymphocyte 
percentages), hemoglobin, hematocrit, and platelets  
o Blood chemistries (creatinine, glucose, total protein, ALT/GPT, AST/GOT, total 
bilirubin)  
 Hemagglutination Inhibition (HAI) titer Day s 0, 1, 3, 7 
 Grade 3 and grade 4 adverse events (AEs ) 
 Serious adverse event s (SAEs) 
 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
13.1 IRB/IEC Approval  
This protocol, informed consent document, relevant supporting information, and all types of subject 
recruitment or advertisement information must be submitted to the IRB/IEC for review and must be 
approved before the study is initiated.  
Any amendments must also be approved by [CONTACT_1201]/IEC prior to implementing changes in the study.  
Protocol IRC00 5  Page 59 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
The site investigator is responsible for keepi[INVESTIGATOR_1683]/IEC apprised of the progress of  the study as 
deemed appropriate, but in any case at least once a year. The site investigator must also keep the IRB/IEC 
informed of any significant AEs. 
13.2 Compliance with Good Clinical Practices (GCP)  
This study will be conducted in compliance with the conditions stipulated by [CONTACT_265953]/IEC, 
informed consent regulations, U.S. FDA regulations, and ICH/GCP Guidelines. In addition, all local 
regulatory requirements will be adhered to, in particular those which afford greater protection to the 
safety of the trial participants.  
13.[ADDRESS_323385]’s study file and be available for verification by [CONTACT_33483].  
In the case of illiterate subjects, the consent form can be read to the subjects. IRB approval for use of the 
oral consent process w ill be obtained if required by [CONTACT_265954].  
If the subject is too ill to consent, the Legally Authorized Representative  may consent for the subject. 
Once the subject is able, the subject will be consented for continuation in the study . 
13.[ADDRESS_323386]’s well -being (45 CFR 46.405). Additionally, this 
research study presents a reasonable opportunity to further the understanding of the treatment of severe 
influenza, which is a serious problem affecting the h ealth or welfare of children (45 CFR 46.40 6). For 
these reasons children are eligible for enrollment into this protocol .  
13.4.[ADDRESS_323387] plasma is frequently used in a critically ill pregnant population. All study plasma 
has tested negative for Zika Virus (as well as other pathogens as previously described  in Section 5.1). For 
these reasons , pregnant women are eligible for enrollment into this protocol.  
13.4.[ADDRESS_323388] benefits of anti-
influenza plasma  to the individual subjects (as suggested by [CONTACT_265955] -influenza plasma), 
participation in the study is allowed for subjects unable to provide informed consent.  
13.4.[ADDRESS_323389] safety.   
Protocol IRC00 5  Page 60 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323390]’s names.  
13.[ADDRESS_323391] 
from work for outpatient visits, and th at fits the local legal and regulatory requirements as well as the 
cultural norm.  
14 DATA MANAGEMENT AND MONITORING  
14.1 Source Documents  
The primary source documents for this study will be the subjects’ medical records. If the investigators 
maintain separate rese arch records, both the medical record and the research records will be considered 
the source documents for the purposes of auditing the study. The investigator will retain a copy of source 
documents. The investigator will permit monitoring and auditing of these data, and will allow NIAID, 
SSS, IRB/IEC, and regulatory authorities access to the original source documents, regardless of media.  
The investigator is responsible for ensuring that the data collected are complete, accurate, and recorded in 
a timely m anner. Source documentation (the point of initial recording of information) should support the 
data collected and entered in to the study database  and must be signed and dated by [CONTACT_265956]/or reviewing the data. All data submitted  should be reviewed by [CONTACT_129778], as appropriate. Data entered into the study database will be 
collected directly from subjects during study visits or will be abstracted from subjects’ medical re cords. 
The subjects’ medical records must record their participation in the clinical trial and what medications 
(with doses and frequency) or other medical interventions or treatments were administered, as well as any 
AEs experienced during the trial.  
14.2 Data Management Plan  
Study data will be collected at the study site(s) and entered into the study database . Data entry is to be 
completed on an ongoing basis during the study.  
14.3 Data Capture Methods  
Clinical data will be entered into a 21 CFR 11 -compliant Internet Data Entry System (IDES). The data 
system includes password protection and internal quality checks to identify data that appear inconsistent, 
incomplete, or inaccurate.  
14.[ADDRESS_323392] Retenti on 
The site investigator is responsible for retaining all essential documents listed in the ICH GCP 
Guidelines. The FDA requires study records to be retained for up to 2 years after marketing approval or 
disapproval (21 CFR 312.62), or until at least [ADDRESS_323393] elapsed since the formal discontinuation of 
clinical development of the investigational agent for a specific indication. These records are also to be 
maintained in compliance with IRB/IEC, state, and federal medical records retention requirements, 
whichever is longest. All stored records are to be kept confidential to the extent provided by [CONTACT_1032], state, 
and local law. It is the site investigator’s responsibility to retain copi[INVESTIGATOR_265903] /DCR/NIAID. No study document should be 
destroyed without prior written agreement between OCRPRO /DCR/NIAID and the Principal Investigator. 
Protocol IRC00 5  Page 61 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
Should the investigator wish to assign the study records to another party and/or move them to anothe r 
location, the site investigator must provide written notification of such intent to OCRPRO /DCR/NIAID 
with the name [CONTACT_40756]/or their new 
location. NIAID must be notified in writing and w ritten NIAID permission must be received by [CONTACT_129779].  
Protocol IRC00 5  Page 62 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
15 REFERENCES  
 
1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K: 
Mortality associated with influenza and respi[INVESTIGATOR_265904]. JAMA 2003, 289(2):179-186. 
2. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, 
Do QH, Guan Y  et al: Oseltamivir resistance during treatment of influenza A (H5N1) 
infection. N Engl J Med 2005, 353(25):2667 -2672. 
3. Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X, Lu J: Passive 
immunotherapy for influenza A H5N1 virus infection with equine hyperimmune 
globulin F(ab' )2 in mice . Respir Res 2006, 7(1):43. 
4. Hanson BJ, Boon ACM, Lim APC, Webb A, Ooi EE, Webby [CONTACT_265957]: Passive 
immunoprophylaxis and therapy with humanized monoclonal antibody specific for 
influenza A H5 hemagglutinin in mice . Respir Res 2006, 7:126. 
5. Luke TC, Kilbane EM, Jackson JL, Hoffman SL: Meta-analysis: convalescent blood 
products for Spanish influenza pneumonia: a future H5N1 treatment?  Ann Intern 
Med 2006, 145(8):599-609. 
6. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai 
KY et al: Convalescent plasma treatment reduce d mortality in patients with severe 
pandemic influenza A (H1N1) [ADDRESS_323394] Dis 2011, 52(4):447-
456. 
7. Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies 
AR, Finfer S, Harrigan PW  et al: Critical care s ervices and 2009 H1N1 influenza in 
Australia and New Zealand . N Engl J Med 2009, 361(20):[ADDRESS_323395] P, Gattas D, 
Granger E, Herkes R  et al: Extracorporeal Membrane Oxygenation for 2009  
Influenza A(H1N1) Acute Respi[INVESTIGATOR_39053] . JAMA 2009, 
302(17):1888 -1895. 
9. Dominguez -Cherit G, Lapi[INVESTIGATOR_265905], Macias AE, Pi[INVESTIGATOR_1946] R, Espi[INVESTIGATOR_53067] -Perez L, de la Torre 
A, Poblano -Morales M, Baltazar -Torres JA, Bautista E, Martinez A  et al: Critically I ll 
patients with 2009 influenza A(H1N1) in Mexico . JAMA 2009, 302(17):1880 -1887. 
10. Kumar A, Zarychanski R, Pi[INVESTIGATOR_1946] R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw 
S, Choong K, Lamontagne F  et al: Critically ill patients with 2009 influenza A(H1N1) 
infection in Canada . JAMA 2009, 302(17):1872 -1879. 
11. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, 
Chow FL  et al: Hyperimmune IV Immunoglobulin Treatment: A Multicenter 
Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza 
A(H1N1) Infection . Chest 2013, 144(2):464-473. 
12. Sekimoto M, Fukui M, Fujita K: Plasma volume estimation using indocyanine green 
with biexponential regression analysis of the decay curves . Anaesthesia 1997, 
52(12):1166 -1172. 
13. Linderkamp O, Versmold HT, Riegel KP, Betke K: Estimation and prediction of blood 
volume in infants and children . Eur J Pediatr 1977, 125(4):227-234. 
14. Anthony MY, Goodall SR, Papouli M, Levene MI: Measurement of plasma volume in 
neonates. Arch Dis Child 1992, 67(1 Spec No):36 -40. 
Protocol IRC00 5  Page 63 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.[ADDRESS_323396], Meredith P, Schmidt PE, Featherstone PI: [INVESTIGATOR_265906] (NEWS) to discriminate patients at risk of early 
cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation 
2013, 84(4):465-470. 
16. Parshuram CS, Bayliss A, Reimer J, Middaugh K, Blanchard N: Implementing the 
Bedside Paediatric Early Warning System in a community hospi[INVESTIGATOR_307]: A prospective 
observational study . Paediatr Child Health 2011, 16(3):e18-22. 
17. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, 
Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ 
dysfunction/failure in intensive care units: results of a multicenter, prospective 
study. Working group on "sepsis -related problems" of the European Society of 
Intensive Care Medicine . Crit Care Med 1998, 26(11):1793 -1800. 
18. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, 
Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to 
describe organ dysfunction/failure. On behalf of the Working Group on Sepsis -
Related Problems of the European Society of Intensive Care Medicine . Intensive 
Care Med 1996, 22(7):707-710. 
19. Pandharipande P P, Shintani AK, Hagerman HE, St Jacques PJ, Rice TW, Sanders NW, 
Ware LB, Bernard GR, Ely EW: Derivation and validation of Spo2/Fio2 ratio to 
impute for Pao2/Fio2 ratio in the respi[INVESTIGATOR_265907] . Crit Care Med 2009, 37(4):1317-1321. 
20. Leteurtre S, Duhamel A, Grandbastien B, Lacroix J, Leclerc F: Paediatric logistic organ 
dysfunction (PELOD) score . Lancet 2006, 367(9514):897; author reply 900 -892. 
21. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbas tien B, Cotting J, Gottesman R, 
Joffe A, Pfenninger J, Hubert P  et al: Validation of the paediatric logistic organ 
dysfunction (PELOD) score: prospective, observational, multicentre study . Lancet 
2003, 362(9379):192 -197. 
22. Force ADT, Ranieri VM, Rubenfel d GD, Thompson BT, Ferguson ND, Caldwell E, Fan 
E, Camporota L, Slutsky AS: Acute respi[INVESTIGATOR_1505]: the Berlin 
Definition . JAMA 2012, 307(23):2526 -2533. 
23. Bux J: Transfusion -related acute lung injury (TRALI): a serious adverse event of 
blood transfusion . Vox Sang 2005, 89(1):1-10. 
24. Pandey S, Vyas GN: Adverse effects of plasma transfusion . Transfusion 2012, [ADDRESS_323397] 1:65S-79S. 
25. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D: Pulmonary embolism after 
intravenous immunoglobulin . J R Soc Med 2001, 94(4):187-188. 
26. Intensive -care patients with severe novel influenza A (H1N1) virus infection - 
Michigan, June 2009 . MMWR Morb Mortal Wkly Rep 2009, 58(27):749-752. 
27. Moser KM, LeMoine JR, Nachtwey FJ, Spragg RG: Deep venous thrombosis an d 
pulmonary embolism. Frequency in a respi[INVESTIGATOR_265908] . Jama 1981, 
246(13):1422 -1424. 
 
 
  
Protocol IRC00 5  Page 64 of 64  
IND [ZIP_CODE]  CONFIDENTIAL  15JUN2017; Version 3.0 
 
16 APPENDIX A  
 
IRC005 will use the Division of AIDS Table for Grading the Severity of Adu lt and Pediatric Adverse 
Events, Version 2.0, November 2014  to grade AEs and laboratory abnormalities.  
 
This table can be found at: https://nirc.s -3.com/irc005/node/1835    
 